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PHARMACOLOGICAL IMPLICATIONS OF ADENOSINE 2A RECEPTOR- 
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G protein-coupled receptors (GPCRs) are heptahelical, transmembrane proteins that 
mediate a plethora of physiological functions by binding ligands and releasing G 
proteins that interact with downstream effectors. GPCRs signal as monomers, 
complexes of the same receptor subtype (homomers), or complexes of different 
receptor subtypes (heteromers). Recently, heteromeric GPCR complexes have become 
attractive targets for drug development since they exhibit distinct signaling and cell-
specific localization from their homomeric counterparts. Yet, the effect of 
heteromerization on the pharmacology of many GPCR homomers remains unknown. 
Therefore, we have undertaken the task to examine the effect of heteromerization on Gs 
signaling through the adenosine 2A receptor (A2AR) and Gi signaling through the 
xiv 
dopamine type 2 receptor (D2R) since the A2AR-D2R heteromer is an emerging 
therapeutic target for Parkinson’s disease (PD). We examined the effect of  
heteromerization on A2AR and D2R homomeric signaling using electrophysiology and 
the Xenopus laevis oocyte heterologous expression system. G protein-coupled inwardly 
rectifying potassium channels (GIRKs) were used as reporters for Gi signaling because 
activation leads to direct Gbeta-gamma (Gβγ)-mediated stimulation of the GIRK current. 
We also coupled GIRK channels to Gs signaling by overexpressing Gαs and signaling 
through Gαsβγ. Our electrophysiological assay is innovative because it allows us to 
optimize the conditions of heteromerization and directly observe GPCR signaling at the 
G protein level. Our data demonstrate that heteromer formation alone decreases 
dopamine-elicited Gi signaling through the D2R and CGS-21680-elicited Gs signaling 
through the A2AR. Furthermore, this reciprocal antagonism was predominately due to 
changes in efficacy versus potency. We also examined crosstalk observing that 
applying agonists or antagonists to the adjacent receptor further modulate this inhibition 
with the combination of agonists and antagonists relieving inhibition. Mutating the A2AR-
D2R heteromer interface abrogated all of the aforementioned ligand-induced effects on 
G protein signaling through the A2AR-D2R heteromer. We are currently aiming to 
validate our results from the oocyte experiments with an in vivo model. Our data further 
elucidate the effect of various ligands on G protein signaling through the A2AR- D2R 
heteromer, which may facilitate future studies that examine A2AR-D2R heteromer 
signaling.  
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Chapter 1 INTRODUCTION 
 
 
 
 
1.1 GPCR signaling  
 
GPCRs are critical for mediating many physiological and pathophysiological 
processes and are thus located on almost every cell type. There are over 800 genes 
encoding GPCRs in the human genome with distinct tissue and subcellular profiles (Lin 
2013). GPCRs have an overall conserved structure including an extracellular amino 
terminus, seven transmembrane (TM) alpha helices, an intracellular carboxy terminus, 
and loops (3 extracellular and 3 intracellular) connecting the 7 TM helices (Ji, 
Grossmann et al. 1998). Various stimuli activate GPCRs including hormones, 
neurotransmitters, odorants, tastants, small molecules, ions, and photons. The majority 
of GPCR signaling involves transducing extracellular stimulation into intracellular 
signaling events through G proteins. GPCR-mediated G protein signaling involves the G 
protein heterotrimer that consists of Gα, Gβ, and Gγ subunits (Lefkowitz 2007). Each 
subunit has distinctive isoforms including 16 Gα, 5 Gβ, and 14 Gγ isoforms that 
assemble in distinct combinations with GPCRs (Milligan and Kostenis 2006). Overall, G 
protein signaling can be functionally grouped into 4 families: Gαi, Gαs, Gαq, and Gα12/13. 
These G proteins have canonical signaling pathways regulating effector proteins, such 
as enzymes, ion channels, and other proteins that in turn modify various intracellular 
2 
second messengers that ultimately mediate physiological responses (Neves, Ram et al. 
2002).  
The molecular rearrangements of the Gα and Gβγ subunits of the heterotrimer 
mediate G protein signaling through GPCRs. In the absence of ligand, the GPCR is in 
an inactive state and the Gα subunit of the heterotrimer, which contains the guanine 
nucleotide binding site is bound to guanine diphosphate (GDP) forming an inactive 
GαGDPβγ heterotrimer complex (Bunemann, Frank et al. 2003). Ligand binding to the 
GPCR promotes a conformational change in the receptor that is transmitted to the Gα 
subunit increasing its affinity for guanine triphosphate (GTP) and promoting the 
exchange of GDP for GTP (Birnbaumer, Abramowitz et al. 1990). The ligand-bound, 
activated receptor is thus serving as a guanine exchange factor (GEF). The exchange 
of GDP for GTP is the rate-limiting step in activating the G protein. Next, there is a 
conformational change allowing the activated GαGTP subunit and the Gβγ subunits to 
interact with downstream effectors such as adenylyl cyclases (AC), phospholipases, ion 
channels, and phosphodiesterases (Fig. 1.2), (Hatcher-Solis et al. 2014). Hydrolysis of 
GTP to GDP by the intrinsic GTPase activity of the Gα subunit promotes a 
conformational rearrangement of the Gα and Gβγ subunits into the inactive GαGDPβγ 
heterotrimer complex (Fig. 1.1) (Li, Wright et al. 2007). GTPase activating proteins 
(GAPs) including regulator of G protein signaling (RGS) proteins accelerate the 
hydrolysis of GTP to GDP inactivating G proteins (Li, Wright et al. 2007). G protein 
signaling is also modulated by cholera toxin (CTX) and pertussis toxin (PTX). CTX ADP-
ribosylates the Gα subunit of Gs proteins at Arg-201 disrupting intrinsic GTPase activity 
rendering the Gαs protein constitutively active (Aktories 2011). Whereas, PTX ADP-
3 
ribosylates the Gα subunit of Gi proteins in the c-terminal Cys-351 moiety functionally 
uncoupling Gi proteins from receptors and reducing their activation (Locht, Coutte et al. 
2011). 
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1.2 The A2AR 
 
Adenosine (ADO) is an endogenous nucleoside produced by the metabolism of 
adenosine triphosphate (ATP) and released along with glutamate from nerve terminals 
and astrocytes (Fuxe, Marcellino et al. 2010). ADO acts on A1, A2A, A2B and A3 
receptors (Ferre, Quiroz et al. 2008).  These receptors are further categorized based on 
their ability to stimulate or inhibit the activity of AC.  Both the A2A and A2B receptors 
couple to Gs through residues in the 3rd intracellular loops of the receptors and stimulate 
the activity of AC.  However, the A1 and A3 receptors couple to Gi through residues in 
the 3rd intracellular loop and carboxy terminus of the receptors and inhibit the activity of 
AC (Cabello, Gandia et al. 2009). The A1 and the A2 receptors function as the two main 
adenosine receptors in the central nervous system (CNS) (Ferre, Quiroz et al. 2008).  
Unlike the widespread distribution of the A1R throughout the brain, the A2 receptor is 
primarily localized in the striatum and mainly concentrated in the GABAergic 
striatopallidal neurons (Fuxe, Marcellino et al. 2010).  Ultrastructural studies suggest 
that A2ARs are localized predominantly in the post-synaptic dendrites and dendritic 
spines of striatal GABAergic neurons even though there is some localization on the pre-
synaptic glutamatergic terminals. The predominantly post-synaptic localization of A2AR 
indicates the significant role adenosine plays in modulating inhibitory output from striatal 
neurons (Hettinger, Lee et al. 2001).   
5 
The A2AR couples to Gs/olf with Golf being the more abundant Gs family G protein 
in the striatum. Via coupling to GS/olf proteins, A2AR stimulates adenylyl cyclase and 
activates the cAMP- protein kinase A (PKA) signaling pathway. This signaling cascade 
results in the phosphorylation of dopamine and cAMP-regulated phosphoprotein 32 kDa 
(DARPP-32), cAMP response element binding protein (CREB), and AMPA receptors. 
Accumulation of cAMP leads to the increase in PKA activation which phosphorylates 
DARPP-32 and CREB resulting in the activation of mitogen-activated protein kinases 
(MAPK), which in turn leads to an increase in expression of different genes such as c-
fos and preproenkephalin in GABAergic, enkephalinergic striatal neurons (Ferre et al. 
2008, Fig.1.3).   
In 2004, Canals et al. provided the first evidence of A2AR homodimerization. 
Förster resonance energy transfer (FRET), bioluminescence resonance energy transfer 
(BRET), and immunoblotting were employed to demonstrate that in transfected HEK-
293 cells the A2AR exists in monomeric and homomeric forms. Using cell surface 
biotinylation experiments, the authors determined that 90% of A2ARs exist as 
homodimers (Canals, Burgueno et al. 2004). Subsequent studies by Gandia and 
colleagues in 2008 using bimolecular fluorescence complementation (BiFC) provided 
additional evidence that A2ARs can form higher order oligomers. The ability of A2ARs to 
form homomers has significant implications for the subunit stoichiometry of heteromers 
that the A2AR forms with various receptors (Gandia, Lluis et al. 2008).  
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1.3 The D2R 
 
Dopamine (DA) is essential for modulating a plethora of central nervous system 
(CNS) functions including mood, feeding, reward, fear, cognition, attention, arousal, and 
voluntary movement (Fuxe, Marcellino et al. 2010). Most dopaminergic innervation in 
the mammalian brain is through 4 major pathways named the nigrostriatal, mesolimbic, 
mesocortical, and tuberoinfundibular systems. The majority of dopaminergic neurons in 
brain modulate fast neurotransmission mediated by GABA and glutamate. DA is the 
endogenous ligand for five different receptors (D1R, D2R, D3R, D4R, D5R) (Cabello, 
Gandia et al. 2009) and is synthesized locally in neurons from its immediate precursor 
L-DOPA, which is synthesized directly from the amino acid tyrosine.  DA receptors can 
be further subdivided as being Gs coupled activators of AC and D1-like (D1, D5), or Gi 
coupled inhibitors of AC and D2-like (D2R, D3R, D4R) (Hasbi, O'Dowd et al. 2011). The 
D1R and D2R are found most prominently in GABAergic striatopallidal neurons and are 
pivotal to motor control through the direct and indirect pathway. The D1-like receptors 
are predominantly localized postsynaptically, whereas the D2-like receptors function 
presynaptically as autoreceptors on dopaminergic neurons and postsynaptically on 
dopamine targeting neurons (Boyd and Mailman 2012). 
The D2R has two splice variants the D2SR (short isoform), which functions 
presynaptically as an autoreceptor and the D2LR (long isoform), which functions 
postsynaptically with important implications for motor control. These two splice variants 
differ by 29 amino acids in the 3rd intracellular loop (Beaulieu and Gainetdinov 2011). 
7 
Presynaptically localized autoreceptors provide a negative feedback regulating neuronal 
firing, synthesis, and release of dopamine in response to changing extracellular 
dopamine levels. Presynaptic D2Rs function to reduce dopamine release in the synapse 
that ultimate leads to decreased motor activity (Boyd and Mailman 2012).  However, 
stimulation of postsynaptic D2Rs results in increased locomotor activity. Pre- and 
postsynaptic D2Rs exert the aforementioned functional effects through Gi/o protein 
signaling (Beaulieu and Gainetdinov 2011).  
G protein signaling through D2Rs regulates ion channels with important 
implications for neuronal excitability. DA binding to D2Rs induces a conformational 
change activating the D2R resulting in the liberation of the Gβγ subunits from the G 
protein heterotrimer. Next, the liberated Gβγ subunits bind to voltage dependent calcium 
channels (VDCC) reducing calcium (Ca2+) influx (Ikeda 1996),(Herlitze, Garcia et al. 
1996). Without Ca2+ influx depolarizing the membrane, the medium spiny neuron (MSN) 
remains hyperpolarized near the potassium equilibrium potential. The released Gβγ 
subunits also bind to the amino and carboxy terminals of GIRKs potentiating their 
activity (Logothetis, Kurachi et al. 1987). Increased potassium efflux also hyperpolarizes 
neurons reducing excitability (Fig.1.4). The ability of the D2R to inhibit neuronal 
excitability is opposed by adenosine (ADO) activating the A2AR (Ferre, Ciruela et al. 
2004).  
In 2009, Han and colleagues engineered an obligate D2R homodimer to elucidate 
G protein signaling through the D2R homomer. Using a Gq signaling based calcium 
mobilization assay, an obligate D2R homodimer was engineered by expressing a wild-
type (WT) D2R protomer incapable of signaling through endogenous Gq proteins in HEK 
8 
cells and a second truncated D2R protomer fused to a chimeric Giq protein unable to 
signal independently due to steric hindrance, but whose signaling was rescued by the 
WT D2R protomer. These obligate D2R homodimers functioned similarly to the GABABR 
requiring both protomers to efficiently bind ligands and signal through G proteins. This 
study demonstrated that agonist binding to one D2R protomer produced activation, but 
agonist binding to both D2R protomers inhibited activation. Additionally, agonist binding 
to one D2R protomer and an inverse agonist binding to the second D2R protomer 
enhanced signaling. These studies suggest that signaling through D2R homomers is 
asymmetrical with activation requiring differential conformational changes from each 
protomer (Han, Moreira et al. 2009).  
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1.4 Evidence for A2AR-D2R heteromerization 
 
 Biochemical and biophysical techniques have provided evidence that the A2AR 
and D2R form a functional heteromeric complex. In 2002, Hillion et al. demonstrated co-
localization of the A2AR and D2R in SH-SY5Y human neuroblastoma cells stably 
transfected with D2R using double immunofluorescence experiments (Fig. 1.5A).  
Immunolabeling experiments were also conducted in neuronal primary cultures of rat 
striatum whereby most neurons exhibited A2AR-D2R immunoreactivity in the dendrites.  
In the same study, co-immunoprecipitation experiments were conducted in membrane 
preparations from D2R transfected SH-SY57 neuroblastoma cells and mouse fibroblast 
Ltk- stably transfected with D2R and transiently co-transfected with the A2AR.  Western 
blots were also utilized to demonstrate co-localization since probing with an antibody 
targeting the D2R was able to pull down the A2AR-D2R heteromer out of solution (Hillion, 
Canals et al. 2002).   
 Furthermore, in 2003 Canals et al. used FRET in HEK-293T cells transfected 
with D2R-GFP2 and A2AR-YFP to determine if the receptors were close enough in 
proximity to produce energy transfer. The FRET efficiency was determined to be in the 
range of 23-25%, while there was significantly lower FRET efficiency in the negative 
control using D2R-GFP2 and CD4-YFP demonstrating the specificity in energy transfer 
between D2R-GFP2 and A2AR-YFP.  Additionally, BRET saturation curves in HEK-293T 
cells co-transfected with a constant amount of A2AR-Rluc construct with increasing 
concentrations of the D2R-YFP plasmid displayed a positive BRET signal for the 
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transfer of energy.  The BRET signal increased as a hyperbolic function of YFP fusion 
construct (Fig.1.5B).  BRET experiments were repeated in the presence of cyclodextrin 
to disrupt membrane rafts to preclude the notion that energy transfer was occurring in 
closely located receptors within plasma membrane microdomains (Canals, Burgueno et 
al. 2004).  A negative control BRET experiment with A2AR-Rluc and GABABR2-YFP lead 
to an undetectable BRET signal. Moreover, undetectable energy transfer was observed 
in BRET saturation experiments using the A2AR and a chimeric dopamine receptor type 
1 (D1R) –D2R, where the regions of the D2R known to interact with the A2AR (helices 5 
and 6, intracellular loop 3) were replaced with the corresponding regions of the D1R, 
which does not interact with A2AR (Canals, Marcellino et al. 2003, Ferre, Ciruela et al. 
2004).  
 In 2011, Trifilieff and colleagues used the proximity ligation assay (PLA) to 
detect co-localization of endogenous A2ARs and D2Rs in ex vivo preparations from 
mouse striatum.  These studies were motivated by concerns that A2AR-D2R co-
localization may not be physiologically relevant because previous studies demonstrating 
co-localization were performed by overexpressing the A2AR and D2R in heterologous 
expression systems. The advantage of PLA is that it can determine the close proximity 
of endogenous proteins in their native state at the single molecule level with high 
specificity. PLA performed on murine striatal slices produced a positive signal for co-
localization of the A2AR and D2R that was absent when the same probes were used in 
knock out (KO) A2AR and D2R mice. These experiments were critical for demonstrating 
the anatomical relevance of A2AR-D2R co-localization in native tissue (Trifilieff, Rives et 
al. 2011). 
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1.5 The A2AR-D2R heteromer Interface 
 Additional experiments have been conducted to determine the A2AR-D2R 
heteromer interface. Canals et al. (2003) performed rigid body docking simulations on 
minimized structures of the A2AR and D2R to determine potential A2AR-D2R heteromer 
interfaces.  The two populations of structures obtained had the amino terminal portion of 
the 3rd intracellular loop of the D2R approaching the 4th helix and carboxy terminal 
portion of the A2AR.  These structures had high docking scores and were consistent with 
BRET experiments involving the D1R-D2R chimera showing that the 3rd intracellular loop 
of the D2R is part of the heteromer interface (Canals, Marcellino et al. 2003).  
 Motivated by the work of Canals et al., Circuela at al. (2004) used biochemical 
pull down assays and mass spectrometry to demonstrate that heteromerization 
depends on electrostatic interactions between an arginine-rich epitope of the amino 
terminal segment of the 3rd intracellular loop of the D2R and phosphorylated Ser374 in 
the carboxy terminus of A2AR (Fig.1.6).  Pull down assays were performed where a GST 
fusion protein containing the carboxy terminal domain of A2AR was able to pull down the 
whole D2R solubilized from transfected HEK cells.  Furthermore, a peptide of the 
arginine rich 3rd intracellular loop of the D2R was able to pull down the carboxy terminus 
of the A2AR as well as the whole A2AR solubilized from transfected HEK-293 cells.  Mass 
spectrometry also showed that the arginine rich 3rd intracellular loop of D2R binds the 
carboxy terminus of the A2AR containing the phosphorylated serine residue (Ciruela, 
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Burgueno et al. 2004).  Likewise, Borroto-Escuela et al. (2010) demonstrated that 
mutagenesis of Ser374 to alanine decreased A2AR-D2R interaction (Figs. 1.6 and 1.7).  
BRET saturation curves in transfected cells established that A2AR-mediated inhibition of 
D2R agonist binding and Gi signaling was also abolished by the A2AR(Ser374) to alanine 
mutation. Thus, an electrostatic interaction between the arginine rich 3rd intracellular 
loop of the D2R and the phosphorylated Ser374 of the carboxy terminal A2AR could 
mediate A2AR-D2R heteromerization (Borroto-Escuela, Marcellino et al. 2010).   
 In 2015, Bonaventura and colleagues used FRET and PLA to demonstrate that 
TM 5s of the A2AR and D2R are involved in heteromerization. FRET experiments were 
conducted in HEK-293 cells transfected with the A2AR fused to the YFP Venus amino 
terminal hemiprotein and the D2R fused to the YFP Venus carboxy terminal 
hemiprotein. A significant fluorescent signal was obtained indicating fusion of the aminio 
and carboxy terminal YFP hemiproteins and A2AR-D2R heteromerization. Next, the 
experimenters used HIV TAT-fused interfering peptides for TM 5 and 7 of each receptor 
to determine the heteromer interface. Peptides for TM 5, but not TM 7 of the A2AR and 
D2R were able to disrupt fluorescence complementation. Using sheep striatal brain 
slices in a PLA, endogenous A2AR-D2R heteromerization was shown in the same study.  
Similar to the FRET experiments, interfering HIV TAT peptides from TMs 5 and 7 were 
used in the PLA and TM 5 but not TM 7 abolished the PLA signal. These findings 
demonstrate that TM 5 of the A2AR and D2R form the heteromer interface as these 
peptides disrupted fluorescence complementation and the PLA signal (Bonaventura, 
Navarro et al. 2015).  
 
13 
 
 
 
 
 
1.6 Reciprocal antagonistic A2AR-D2R interactions  
 
The antagonistic interaction involving the ability of the A2AR to modulate the 
effect of D2Rs on ligand binding, neurotransmitter release, neuronal excitability, and 
motor activity is critical for striatal function (Ferre, Quiroz et al. 2008). Several different 
research groups have demonstrated an antagonistic A2A-D2R interaction using 
competitive radioligand-binding experiments in membrane preparations from transfected 
cell lines, and in human and rat striatum. In these experiments, the application of a 
selective A2AR agonist diminished the capacity of a D2R agonist to displace the binding 
of a discriminatory D2R ligand (Ferre, von Euler et al. 1991, Dasgupta, Ferre et al. 1996, 
Kull, Ferre et al. 1999, Salim, Ferre et al. 2000, Diaz-Cabiale, Hurd et al. 2001).  
Subsequent experiments established the antagonistic A2AR-D2R interaction 
whereby stimulating the A2AR counteracts D2R mediated inhibition of neurotransmitter 
release (Ferre, Quiroz et al. 2008). Ferré et al. (1993) showed the antagonistic A2AR-
D2R interaction experimentally through in vivo microdialysis experiments whereby 
perfusion of a D2R agonist into the dorsal striatum caused a decrease in the 
extracellular levels of the neurotransmitter GABA in the globus pallidus (Ferre, Snaprud 
et al. 1993). Conversely, when an A2AR agonist was perfused, there were no direct 
effects, but the action of a D2R agonist was blocked (Ferre, Snaprud et al. 1993). In the 
ventral striatum, D2Rs exert a more tonic stimulation through endogenous DA on 
neurotransmitter release from GABAergic enkephalinergic neurons. Consequently, 
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ventral striatal perfusion of an A2AR agonist increased the extracellular levels of GABA 
in the ventral pallidum acting as a D2R antagonist (Ferre, O'Connor et al. 1994).   
The ability of the A2AR to antagonize D2R mediated inhibition of neuronal firing 
has also been well characterized (Ferre, Quiroz et al. 2008). Striatal output is 
determined by the firing frequency of inhibitory GABAergic MSNs. Corticospinal inputs 
to the striatum depolarize GABAergic MSNs from a resting hyperpolarized membrane 
potential activating D2Rs preventing MSNs from transitioning to a more depolarized 
membrane potential. Azdad et al. (2009) conducted experiments utilizing perforated 
patch clamp recordings from brain slices to demonstrate the role of A2AR-D2R 
interactions in regulating the membrane potential transitions of striatopallidal neurons. 
Application of a D2R agonist hyperpolarized the striatal MSNs and abolished the firing 
(Azdad, Gall et al. 2009). Ensuing application of an A2AR agonist failed to modify 
neuronal state transitions or firing frequency, but reversed the effect of the D2R 
activation. The ability of A2AR agonists to disinhibit neuronal firing was blocked by A2AR 
antagonists.  Furthermore, A2AR ligands had no effect on neuronal firing in A2AR KO 
mice (Azdad, Gall et al. 2009).   
Similar to neurotransmitter release and neuronal excitability, motor activity is also 
governed by the antagonistic A2A-D2R interaction.  Several experiments have revealed 
the ability of selective A2AR ligands to offset or potentiate the motor activation created 
by D2R agonists (Ferre, Herrera-Marschitz et al. 1991, Rimondini, Ferre et al. 1998, 
Ferre, Popoli et al. 2001). Ferré et al. (2009) performed behavioral experiments in 
neurotoxin induced DA depleted rats showing that the A2AR agonist CGS 21680 
attenuated the effects of a D2R agonist quinpirole on turning behavior (Ferre, Baler et al. 
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2009). Accordingly, Stromberg et al. 2000 demonstrated that an A2AR antagonist MSX-3 
significantly potentiated the quinpirole induced turning behavior of DA denervated rats.  
These experiments argued for a specific A2AR-D2R interaction in enkephalinergic striatal 
neurons because MSX-3 did not significantly alter the turning behavior of rats given the 
D1R agonist SKF 38393 (Stromberg, Popoli et al. 2000).   
Fewer studies have examined antagonism of the D2R on A2AR signaling and 
binding. Signaling through the A2AR results in cAMP accumulation, CREB 
phosphorylation and an increase in c-fos expression. Under physiological conditions, 
the D2Rs exhibit a steady activation that impedes the ability of A2ARs to signal through 
the cAMP-PKA pathway (Konradi and Heckers 1995).  Experimental demonstrations in 
rodent striatum show that in vivo administration of D2R antagonists produces a 
significant increase in the PKA dependent phosphorylation of DARPP-32 or the AMPA 
receptor resulting in an increase in the expression of c-fos or preproenkephalin genes. 
This increase in gene expression depends on the ability of the antagonist to block the 
D2R and release A2AR signaling stimulated by endogenous ADO (Pollack and Fink 
1995). In the antagonistic A2AR-D2R interaction at the second messenger level, the D2R 
receptor lacks an independent effect on gene expression, but stimulation of the D2R 
receptor counteracts the effects of A2AR receptor stimulation (Svenningsson, Lindskog 
et al. 2000).   
In 2013, Fernandez-Duenas and colleagues developed a novel A2AR fluorescent 
ligand MRS5424 and used real-time FRET along with flow cytometry to examine the 
effect of the D2R on A2AR agonist binding. HEK-293 cells were transfected with A2AR-
CFP and D2R-AGT and co-localization of the A2AR and D2R was visualized using SNAP 
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tag technology. Real-time FRET experiments demonstrated that binding of the A2AR 
agonist MRS5424 was reduced upon perfusion of the D2R agonists pramipexole, 
rotigotine, and apomorphine. In cells transfected only with the A2AR, perfusion of the 
previously mentioned D2R agonists had no effect on MRS5424 binding. Flow cytometry 
was also conducted with similar results to the real-time FRET experiments where the 
D2R agonists pramipexole, rotigotine, and apomorphine caused a significant reduction 
in MRS5424 binding to the A2AR. These experiments provide evidence for agonists 
binding to the D2R acting as negative allosteric modulators of agonist binding to the 
A2AR (Fernandez-Duenas, Gomez-Soler et al. 2013).   
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1.7 The Basal Ganglia and the A2AR-D2R Heteromer  
 
 Essential for the planning and initiation of movement, the basal ganglia are a 
group of subcortical nuclei consisting of the caudate nucleus, putamen, globus pallidus, 
substantia nigra, and the subthalamic nucleus (STN).  The purpose of the basal ganglia 
circuit is to process incoming signals from the cortex and to relay an output signal to the 
cortex through the thalamus to execute voluntary movement. Consisting of the caudate 
nucleus, putamen, and nucleus accumbens, the striatum is the main input structure of 
the basal ganglia circuit (Blandini, Nappi et al. 2000). The major neural innervations of 
the striatum that are relevant to our study consist of excitatory glutamatergic projections 
from nearly all cortical areas and dopaminergic inputs from the substantia nigra pars 
compacta (Fig. 1.9(McGeorge and Faull 1989, Blandini, Nappi et al. 2000)). MSNs 
comprise over 95% of the striatum with GABA being the main neurotransmitter of these 
neurons (Kemp and Powell 1971, Kita and Kitai 1988). Within the MSNs, GABA can be 
co-localized with either enkephalin or substance P/dynorphin.  Enkephalinergic MSNs 
contain A2ARs and D2R and project to the external segment of the globus pallidus; 
whereas, dynorphinergic MSNs contain A1Rs and D1Rs and project to the internal 
segment of the globus pallidus (Fig. 1.9). The striatal organization of enkephalinergic 
and dynorphinergic MSNs form the basis for the direct and indirect motor pathways 
(Blandini, Nappi et al. 2000).  
Two main striatal motor pathways regulate the output from the basal ganglia: the 
direct and indirect pathways. We will focus on the indirect pathway since it involves the 
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A2AR-D2R heteromer and is implicated in PD (Kull, Ferre et al. 1999). Under 
physiological conditions, striatal MSNs expressing the A2AR-D2R heteromer receive 
dopaminergic input from the substantia nigra pars compacta. In the striatum, D2R 
signaling inhibits neuronal excitability and reduces inhibitory GABAergic output to the 
external segment of the globus pallidus (Gpe) (Lang and Lozano 1998, Blandini, Nappi 
et al. 2000). Through heteromerization, the A2AR is critical in modulating neuronal 
excitability and GABA release by counterbalancing D2R signaling. Next, the tonically 
active inhibitory neurons of the Gpe relay to provide tonic, inhibitory GABAergic 
projections to the STN. Then, the STN conducts transient, glutamatergic excitatory 
output to the internal segment of the globus pallidus (Gpi). The Gpi subsequently sends 
a tonic inhibition to the ventrolateral thalamus. Consequently, the ventrolateral thalamus 
sends a transient excitatory projection to the motor cortex to initiate movement (Fig. 1.8 
left, (Lang and Lozano 1998)). Overall, the signaling balance through the A2AR-D2R 
heteromeric complex is a critical component of the indirect motor pathway regulating the 
neuronal excitability of striatal GABAergic MSNs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
19 
 
 
 
 
 
1.8 The A2AR-D2R Heteromer and the significance for Parkinson’s disease 
 
Discovered by James Parkinson in 1817, PD is the second most common 
neurodegenerative disease affecting 1-2% of people over the age of 60. For most 
patients, there is a slow progression of the disease between the ages of 50 and 70 
followed by death 10 to 20 years later (Lang and Lozano 1998). The etiology of PD 
remains unclear, but considerable research has led to the notion that genetic 
predisposition and exposure to pesticides contributes to disease formation. The 
hallmark of PD is the formation of Lewy bodies (aggregates of α-synuclein) and the 
progressive deterioration of dopaminergic neurons in the substantia nigra pars 
compacta (Lozano, Lang et al. 1998). After loss of approximately 80% of dopaminergic 
neurons in the substantia nigra, Parkinsonian symptoms appear including a decrease in 
spontaneous movement, postural instability, bradykinesia, rigidity, and a resting tremor 
(Lang and Lozano 1998).  These defects in motor function are attributable to increased 
inhibitory output from the basal ganglia causing decreased thalamic activation of the 
motor cortex (Lang and Lozano 1998).  
In cases of PD, decreased homomeric dopaminergic signaling through the D2R 
along with antagonism of the A2AR on the residual D2R signaling will increase inhibitory 
GABAergic projections from the basal ganglia to the ventrolateral thalamus thus 
diminishing excitatory thalamic output to the motor cortex (Fig.1.8 right, (Kull, Ferre et 
al. 1999)). The excessive inhibition of thalamocortical projections causes Parkinsonian 
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symptoms. Currently, there is no cure for PD, but D2R agonists and A2AR antagonists 
are used clinically to manage motor dysfunction (Jenner 2003).   
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1.9 Antiparkinsonian therapeutics targeting the A2AR-D2R Heteromer 
 
Symptomatic management of PD is based on using D2R agonists to mimic DA 
mediated neurotransmission in the nigrostriatal pathway.  Levodopa (L- DOPA), the 
immediate precursor of DA, is highly effective in managing the early stages of PD 
(Jenner 2003).  However, adverse side effects caused by D2R agonists include nausea, 
vomiting and hypotension.  Chronic side effects include dyskinesia, psychosis and loss 
of drug efficacy. Furthermore, D2R agonists do not alleviate the Parkinsonian symptom 
of postural instability or address the neurodegeneration responsible for the advent of 
motor dysfunction (Jenner 2003). In order to circumvent the problems associated with 
D2R agonists, researchers have explored the use of A2AR antagonists based on the 
well-characterized antagonistic interaction between the A2AR and the D2R.   
A2AR antagonists that inhibit postsynaptic A2ARs in enkephalinergic MSNs would 
be beneficial for the treatment of PD through inhibiting the indirect motor pathway and 
increasing motor activity. However, A2AR antagonists that inhibit presynaptic A2ARs that 
contact dynorphinergic MSNs would decrease glutamate release in the direct motor 
pathway inhibiting motor activity. Thus, antiparkinsonian therapeutics targeting the A2AR 
should have a higher affinity for postsynaptic versus presynaptic A2ARs. In 2011, Orrú 
and colleagues used radioligand-binding experiments in stable cell lines containing 
A2ARs, A2AR-D2R heteromers (postsynaptic A2ARs), and A2AR-A1R heteromers 
(presynaptic A2ARs). Among the A2AR antagonists tested, SCH 442416 had the lowest 
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affinity in cell lines containing A2AR-D2R heteromers whereas istradefylline (KW-6002) 
had the highest relative affinity in cells containing A2AR-D2R heteromers. Additional 
studies demonstrated that KW-6002 reduced motor impairment in neurotoxin induced 
Parkinsonism animal models (Orru, Bakesova et al. 2011). Therefore, KW-6002 was 
examined as a promising antiparkinsonian therapeutic as it targets postsynaptic A2AR-
D2R heteromers increasing motor activity.  
The majority of information available on the effectiveness of A2AR antagonists in 
PD patients was collected in clinical trials with KW-6002. Phase IIa clinical trials with 
KW-6002 suggest that the drug has antiparkinsonian actions significantly reducing 
motor deficits in advanced PD patients. According to the study, KW-6002 had no effect 
on Parkinsonian symptoms when solely administered. However, when combined with a 
low dose of L-DOPA, patients experienced improved motor function comparable to an 
optimal dose of L-DOPA alone.  Combining KW-6002 with L-DOPA reduced side effects 
with patients experiencing milder dyskinesia, dizziness, insomnia and nausea.  Only 5% 
of patients experienced increased anxiety.  When KW-6002 was co-administered with L-
DOPA, the half-life of L-DOPA was prolonged (Chen, Wang et al. 2013).  Despite these 
promising results, KW-6002 did not receive FDA approval in 2008, but it ignited further 
studies into A2AR antagonists as antiparkinsonian drugs (Armentero et al. 2011). In 
March of 2013, KW-6002 became the first A2AR antagonist approved for treatment of 
PD in Japan.  As of 2014, clinical trials were in progress for the following A2AR 
antagonists: phase I for PBS-509, ST1535, ST4206 and V81444; phase II for 
tozadenant. Learning more about signaling through the A2AR-D2R heteromeric complex 
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will facilitate the development of novel and more efficacious medications for PD 
(Armentero, Pinna et al. 2011).  
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1.10 Conclusion  
Homomeric G protein receptor signaling has been characterized for many years, 
but recent data suggest that many GPCRs form oligomeric complexes with distinct 
signaling properties. The effect of heteromerization on the pharmacology and signaling 
of many GPCR homomers is still not well understood. Thus, GPCR heteromers provide 
new therapeutic targets and research into the signaling of heteromers could provide 
novel therapeutics for important diseases. The Gαs/olf coupled A2AR and the Gαi/o coupled 
D2R are two distinct GPCRs that heteromerize in the dorsal and ventral striatopallidal 
GABA pathway (Ferre, Quiroz et al. 2008). The physiological relevance of the A2AR-D2R 
heteromer is based on receptor antagonism. A2ARs antagonize the inhibitory role of 
D2Rs on neurotransmitter release, neuronal firing, and locomotor activity.  There is 
exaggerated antagonism of the D2R by the A2AR in Parkinson’s disease patients due to 
decreased dopaminergic tone in the striatum (Kull, Ferre et al. 1999). Therefore, A2AR 
antagonists are being explored as possible therapeutics for Parkinson’s disease 
because they alleviate the A2AR inhibition of the D2R (Ferre, Ciruela et al. 2007). D2Rs 
also antagonize A2AR agonist binding and at the second messenger level. The A2AR-
D2R heteromer is an emerging therapeutic target for dysfunctional dopaminergic 
signaling and studies examining G protein signaling through the heteromer could yield 
important insight for drug development.  
 
25 
 
 
 
1.11 Hypothesis 
  Based on previous studies elucidating reciprocal antagonistic A2AR-D2R 
interactions, we hypothesized that A2AR-D2R heteromerization would reduce both D2R-
mediated Gi signaling and A2AR-mediated Gs signaling. To test our hypothesis, we 
studied A2AR-D2R heteromer cross signaling by expressing the GPCRs as well as 
reporter channels using the Xenopus oocyte heterologous expression system. Our 
electrophysiological assay is innovative in that it will allow us to control the conditions of 
heteromerization to tease apart the differences from homomeric or monomeric 
signaling. By monitoring the current through the reporter channel, we found that A2AR-
D2R heteromerization inhibited both D2R-mediated Gi signaling and A2AR-mediated Gs 
signaling even when the adjacent receptor was unliganded and perfusion of specific 
ligand combinations targeting the A2AR-D2R heteromer induced crosstalk and 
modulated this inhibition. After completing our in vitro experiments in Xenopus oocytes, 
we transitioned to an in vivo system utilizing a novel optogenetics-microdialysis assay 
and examined the effects of A2AR antagonists on striatal glutamatergic release. We 
demonstrated that A2AR antagonists with a preferred presynaptic profile were able to 
inhibit the release of glutamate; whereas, A2AR antagonists with a preferred 
postsynaptic profile targeting the A2AR-D2R heteromer were not able to inhibit striatal 
glutamate release.  
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Figure 1.1 The G protein cycle. Ligand binding to the GPCR promotes a 
conformational change in the receptor that is transmitted to the Gα subunit increasing its 
affinity for guanine triphosphate (GTP) and promoting the exchange of GDP for GTP. 
Next, the activated Gα subunit dissociates from the Gβγ subunits allowing interactions 
with downstream effectors. Hydrolysis of GTP to GDP by the intrinsic or stimulated 
GTPase activity of the Gα subunit promotes reassociation of the Gα and Gβγ subunits 
into the inactive heterotrimer complex. Adopted from Li et al., 2007.  
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Figure 1.2  Gi/o- and Gs-coupled Receptor Signaling. Receptor stimulation results in 
the liberation of Gβγ subunits from the G protein heterotrimer that are free to bind to 
nearby GIRKs potentiating their current. Adapted from Hatcher-Solis et al. 2014.  
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Figure 1.3  A2AR Signaling. Diagram showing the predominantly postsynaptic 
localization of A2ARs along with A2AR signaling.   
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Figure 1.4  D2R Localization and Signaling. Diagram showing the pre- and 
postsynaptic localization of D2Rs along with D2R signaling affecting neuronal excitability.  
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Figure 1.5  A2AR and D2R Co-localization. (A) SH-SY5Y human neuroblastoma cells 
stably transfected with D2R (a) A2AR immunoreactivity, (b) D2R immunoreactivity, and 
(c) A2AR-D2R colocalization. Adapted from Hillion et al. 2002. (B) Competition BRET 
saturation curve of HEK-293 cell co-transfected with A2AR and D2R. A2AR-Rluc and D2R-
YFP (squares) or A2AR-Rluc and GABABR2-YFP (triangle). Adapted from Canals et al. 
2003.  
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Figure 1.6  The A2AR-D2R Heteromer Interface. (A) WT D2R (red) with arginine rich 3rd 
intracellular loop. D2R (blue) with arginine to alanine mutations in the 3rd intracellular 
loop. (B) BRET saturation curve for A2AR-D2R (red) and  A2AR-D2R(R-A) (blue). Adapted 
from Circuela et al. 2004. 
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Figure 1.7  The A2AR-D2R Heteromer Interface Continued.  (A) Snake plot of the WT 
A2AR. (B) BRET saturation curve of the D2R-Rluc and A2AR-YFP (red),  D2R-Rluc and 
A2AR-YFP(S374A, grey), D2R-Rluc and A2AR(DD)-YFP (white), and D2R-Rluc and 
A2AR(SDD)-YFP (black). Adapted from Escuela et al. 2010.  
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Figure 1.8 The Indirect Motor Pathway. Diagram of the indirect motor pathway (left) 
and the alterations in signaling that occur during PD (right).  
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Figure 1.9  Pre- and Postsynaptic Localization of A2ARs and D2Rs. A2ARs are co-
localized with D2Rs postsynaptically in the dendritic spines of enkephalinergic medium 
spiny neurons in the striatum. A2ARs are also co-localized with A1Rs presynaptically in 
glutamatergic afferents to enkephalinergic and dynorphynergic medium spiny neurons.  
D2R are similarly located presynaptically in glutamatergic and dopaminergic afferents 
projecting to enkephalinergic and dynorphynergic medium spiny neurons. Adapted from 
Ferre 2008. 
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Chapter 2 MATERIALS AND METHDOS 
 
2.1 Molecular Biology 
 The following cDNAs used in the Xenopus oocyte heterologous expression 
system were subcloned into the pXOOM oocyte expression vector: mD2R, 3HA-hA2AR, 
m-PHOS, D2R(9A), A2AR(S374A), Kir 3.2,  and βARK. Previous studies in the lab 
provided the following cDNAs subcloned into the pGEMHE oocyte expression vector Kir 
3.1, Gαs, and PTX. Linearized and purified (Pure Link PCR Purification kit, Thermo 
Fisher Scientific) plasmids were transcribed using an mMESSAGE mMACHINE T7 
Transcription kit (Thermo Fisher Scientific). Mutations were performed using a standard 
Pfu-based mutagenesis protocol and were verified using sequencing (Genewiz).  
 
2.2 Reagents 
 CGS 21680, KW-6002, SCH44216, N6-cyclopentyladenosine, and paliperidone 
were purchased from Tocris. Dopamine, amisulpride, adenosine, and quinpirole were 
purchased from Sigma. SCH44216 used in the microdialysis experiments was kindly 
provided by the CHDI foundation. CGS 21680, KW-6002, and SCH44216 were 
dissolved in DMSO at a dilution that was less than 1% DMSO. Dopamine, amisulpride, 
paliperidone, adenosine, N6-cyclopentyladenosine, and quinpirole were dissolved in 
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water. SCH44216 used in the microdialysis experiments was dissolved in a mixture of 
tween-80 detergent and DMSO.  
 
2.3 Oocyte preparation and injection  
 Xenopus laevis (African clawed frog) colonies (Xenopus Express) were 
maintained at the Virginia Commonwealth University according to IACUC approved 
protocols. The Xenopus laevis surgeries conducted in this study were approved by 
protocol AD20112: Heterologous Expression Studies in Xenopus laevis Oocytes. 
Briefly, Xenopus were anesthetized with a buffered Tricaine solution and ovarian tissue 
was excised unilaterally. Excised oocytes were defolliculated using a collagenase 
solution following standard protocols (Logothetis, Movahedi et al. 1992). Oocytes were 
then washed and incubated at 180 C in an OR2 solution with 2 mM Ca2+ and Penicillin/ 
Streptomycin antibiotics.  Oocytes at stage V or VI of maturation were selected for 
microinjection of 0.5-2 ng of cRNA suspended in DEPC treated water. Injected oocytes 
were incubated for 2-3 days at 18 0C to allow for optimal protein expression.  
  
2.4 Two-electrode voltage-clamp 
 Borosilicate glass tubing was pulled using a Flaming-Brown micropipette puller. 
The micropipettes were then back filled with a 3 M KCl solution that was1.4% agarose. 
Acceptable resistances for the micropipettes were between .1 and 1 MΩ. Two-electrode 
voltage-clamp whole-cell current recordings for the Gi and Gs assay were performed 
using a GeneClamp 500 amplifier (Axon Laboratories). Oocytes were held at 0 mV (Ek) 
and the current was monitored using a 800 ms ramp protocol with a command potential 
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from -80 mV to +80 mV to assess the inward and outward currents. Basal current 
through the GIRK channel was measured in a ND96K solution (HK, 96 mM KCl, 10 mM 
HEPES-K, 1 mM MgCl2, and 1.8 mM CaCl2. 3 mM Barium Chloride (Ba2+) in HK was 
used to block the GIRK current. Only the Barium-sensitive current was used for the 
statistical analysis.  Each data set consisted of 5-10 recordings, each from separate 
oocytes. Experiments were repeated using oocytes from at least 2 different frogs.  
 
2.5 Experimental Mice 
 WT C57BL/6 mice (Charles River Laboratories) were housed four per cage and 
kept on a 12 h light/ dark cycle with food and water available ad libitum. All mice used in 
this study were maintained in accordance with the guidelines of the National Institutes of 
Health Animal Care and the mouse research conducted to perform this study was 
approved by the NIDA IRP Animal Care and Use Committee protocol no. 12-BNRN-73.  
 
2.6 Craniotomy surgical procedures  
 For all craniotomy surgical procedures, mice were anesthetized with a 
combination of ketamine and xylazine (NIDA Pharmacy) and placed in a stereotaxic 
apparatus. For optogenetic-microdialysis experiments, mice received unilateral 
injections of adeno-associated virus (AAV) encoding channel rhodopsin 2 (ChR2) fused 
to enhanced yellow fluorescent protein (EYFP) under control of the CaMKII neuronal 
promoter (AAV-CaMKIIa-hChR2(H134R)-EYFP; University of North Carolina core 
vector facility) in the motor cortex. The coordinates of virus injection were 1.9 mm 
anterior, 1.6 mm lateral, and 1.8 mm ventral with respect to bregma. See Quiroz, Orru 
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et al. 2016 for detailed a protocol of virus injection. Approximately, 4 weeks after virus 
injection a modified microdialysis probe with an embedded light-guiding optic fiber 
(Quiroz, Orru et al. 2016) was implanted in the striatum. The coordinates for probe 
implantation were 0.3 mm posterior, 2.7 mm lateral and 4.2 mm ventral with respect to 
bregma. The optogenetic microdialysis probes were fixed to the skull with dental cement 
and acrylic resin.  
 
2.7 Optogenetic stimulation 
 Optical stimulation was delivered by coupling the light guiding port of the 
implanted optogenetic-microdialysis probe to a 473 nm solid-state laser module driven 
by an electrical stimulator (Gross S88 Stimulator). Light was administered over a 20 min 
period in 160 ms trains of 2 ms pulses at 100 Hz with a light intensity of 5-8 mW at the 
probe tip. The light intensity delivered through the probe was measured using an 
integrating sphere silicon photodiode power sensor designed for optical power 
measurements independent of beam shape and divergence (model S144C, Thor labs).  
 
2.8 In vivo Microdialysis 
 Microdialysis sampling was performed with optogenetic stimulation to analyze the 
extracellular concentration of glutamate in the striatum of freely moving mice 48 hrs. 
after probe implantation. An artificial cerebrospinal fluid (aCSF) containing the following 
in mM (144 NaCl, 4.8 KCl, 1.7 CaCl2 and 1.2 MgCl2) was perfused through the 
optogenetic-microdialysis probe for the entire duration of the experiment. Perfusion was 
at a constant rate of 0.5 µL/min and drugs were delivered through intraperitoneal (i.p.) 
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injection. Sampling was obtained manually at 10 min intervals for 180 minutes. The first 
60 min were to examine basal glutamate measurements and the final 120 were to 
examine extracellular glutamate release in response to drug administration followed by 
20 min of optogenetic stimulation. Extracellular glutamate was measured by HPLC 
coupled to a glutamate oxidase enzyme reactor and electrochemical detector (Eicom). 
After the microdialysis experiments, the mice were anesthetized with Equithesin (NIDA 
pharmacy) and perfused transcardially with 0.1 M PBS pH 7.4 followed by 4% 
formaldehyde in 0.1 M PBS. Brains were stored in the same fixative for 2 hrs and then 
stored in 30% sucrose in 0.1 M PBS for 48 hrs at 40 C. Brains were then sliced in 40 µm 
coronal sections using a Leica CM3050S cryostat at -200 C. The brain slices were 
collected in PBS and stored in antifreeze-buffered solution (20% ethylene glycol, 10% 
glycerol, and 10% sucrose in PBS) at -800 C until processing. Slices were imaged using 
confocal fluorescence microscopy acquired with a Zeiss microscope (Examiner Z1) 
fitted with a confocal laser module (LSM-710, Zeiss).  
 
2.9 Erk 1/2 Immunohistochemistry 
 Fixed brain slices (see previous section) were stained according to the protocol 
detailed in Quiroz-Molina et al. 2015. Briefly, the brain slices were rinsed in PBS and 
incubated in blocking buffer before incubation with rabbit polyclonal anti-phospho-
Thr202/Tyr204 ERK1/2 antibody in blocking buffer. Sections were then washed and 
incubated in biotinylated goat anti-rabbit antibody. The samples were subsequently 
washed and incubated in ABC reagent and washed again before treatment with DAB, 
ammonium nickel sulfate, and hydrogen peroxide until development. The samples were 
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then mounted onto treated glass slides, dehydrated, cleared in xylene, and coverslipped 
with DPX. Images were acquired using confocal microscopy (see previous section).  
 
2.10 Statistics 
 All data were expressed as mean ± standard error of the mean (SEM), unless 
otherwise indicated. Error bars in each figure represent standard error of the mean 
(SEM). In the oocyte experiments, statistical significance between 2 groups was 
assessed using an unpaired t-test with an assumption of unequal variance (OriginLab).  
When multiple groups were analyzed, a one-way ANOVA followed by Tukey’s posthoc 
test was used (OriginLab). Gi and Gs activities were determined by normalizing the drug-
induced current to the basal GIRK current in HK and subtracting out the barium 
insensitive current. For the microdialysis experiments, extracellular glutamate 
measurements were normalized to the basal measurements before optogenetic 
stimulation and drug administration, n=3-6. When multiple groups were analyzed, a one-
way ANOVA followed by a Tukey’s posthoc test was used (Prism). The optogenetics-
microdialysis experiments were analyzed using a two-way repeated-measures ANOVA 
followed by a Tukey’s posthoc test (Prism). For all statistical analyses, significance was 
determined using p<0.05.   
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Chapter 3  THE EFFECT OF A2AR-D2R HETEROMERIZATION ON GI SIGNALING 
THROUGH THE D2R 
 
3.1 Introduction  
 The Gi-coupled D2R and the Gs-coupled A2AR are co-localized in the 
striatum on GABAergic MSNs (Fuxe, Ferre et al. 2007). Biochemical pull down assays 
and biophysical BRET and FRET techniques have provided evidence that the A2AR and 
D2R form a functional heteromeric complex (Canals, Marcellino et al. 2003). Previous 
studies determined that the heteromer interface depends on electrostatic interactions 
between an arginine rich region in the third intracellular loop of the D2R and a 
phosphorylated serine (Ser374) in the carboxy terminus of the A2AR (Borroto-Escuela, 
Marcellino et al. 2010). Homomeric D2R and A2AR receptor signaling cascades have 
been well established, but the implications of receptor heteromerization are not well 
understood.  In MSNs, homomeric D2R signaling through the Gi/o protein inhibits 
neuronal excitability. In contrast, the Gs/olf protein-coupled A2AR is critical in modulating 
the excitation of striatal neurons by antagonizing the D2R through the formation of a 
higher order oligomer (Fuxe, Ferre et al. 2007). Thus, through heteromer crosstalk A2AR 
agonists act as D2R antagonists exerting an excitatory role on the function of MSNs 
(Ferre, Quiroz et al. 2008). This receptor-mediated antagonism has important 
implications for the indirect motor pathway circuitry in the basal ganglia. In cases of 
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Parkinson’s disease, decreased dopaminergic signaling through the D2R along with 
antagonism of the A2AR on residual D2R signaling through heteromerization increases 
inhibitory GABAergic projections from the basal ganglia to the ventrolateral thalamus, 
disrupting excitatory thalamic output to the motor cortex. Thus, A2AR antagonists are 
being explored in clinical trials as antiparkinsonian therapeutics to alleviate A2AR-
mediated inhibition on D2R signaling (Quiroz et al. 2009) The A2AR-D2R heteromer is an 
emerging target for Parkinson’s disease pharmacotherapy and understanding the 
signaling balance through the heteromer is paramount. 
 In this study, we examine the effect of A2AR-D2R heteromerization on the 
pharmacology of D2R signaling. Previous studies lead us to postulate that the A2AR and 
D2R receptor are inversely coupled through heteromeric assembly similar to the 
serotonin 2A- metabotropic glutamate type 2 receptor heteromer, which was previously 
characterized by our lab (Fribourg, Moreno et al. 2011). Therefore, we hypothesize 
A2AR-D2R heteromerization induces reciprocal antagonism whereby A2AR receptor 
stimulation inhibits D2R signaling making the combination of D2R agonists and A2AR 
antagonists or inverse agonists promising new therapeutics for Parkinson’s disease 
because they maximize dopaminergic signaling. In order to test this hypothesis, we 
have developed electrophysiological assays to study A2AR-D2R heteromer cross 
signaling by expressing the GPCRs together with reporter channels in the Xenopus 
oocyte heterologous expression system. Our electrophysiological assay is innovative in 
that it allows us to control the conditions of heteromerization and tease apart the 
differences from protomer signaling. By monitoring the current through the reporter 
channel, we anticipate perfusion of specific ligand combinations targeting the A2AR-D2R 
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heteromer will maximize GPCR signaling versus individual drug administration targeting 
A2ARs or D2Rs. 
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3.2 Results  
 G protein-sensitive inwardly rectifying K+ (GIRK) channels can serve as 
reporters for Gi signaling through the D2R and Gs signaling through the A2AR (Hatcher-
Solis, Fribourg et al. 2014). We chose the GIRK1/2 (G1/2) channel heterotetramer as a 
reporter for G protein signaling because it is co-localized with the A2AR and D2R on the 
postsynaptic site of dopaminergic MSNs. The G1/2 channel can be used as a reporter 
for Gi or Gs signaling because GPCR activation results in liberation of the beta gamma 
subunits (Gβγ) from the G protein heterotrimer that bind to a cleft formed by cytosolic 
loops of adjacent subunits of the channel, potentiating its current (Mahajan, Ha et al. 
2013). For our electrophysiological assays, we used Xenopus laevis oocytes as our 
heterologous expression system and conducted two-electrode voltage-clamp recordings 
using a voltage ramp protocol form -80 mV to +80 mV two days following cRNA 
injection.  
Figure 3.1 establishes G1/2 as a suitable reporter for D2R signaling. Basal G1/2 
current in a high potassium (HK) buffer is not sensitive to 1 µM dopamine (DA) without 
D2R co-expression (Fig. 3.1A). However, when G1/2 is co-expressed with the D2R, 
there is a robust inward DA-elicited current (Fig.3.1B). The DA-elicited current is Gi-
mediated as it is blocked by co-expression of pertussis toxin (PTX, Fig. 3.1C). PTX 
abrogates Gi signaling by catalyzing the ADP-ribosylation of the Gαi subunit, physically 
uncoupling the G protein from the GPCR (Hatcher-Solis, Fribourg et al. 2014). The DA-
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elicited current is also Gβγ-mediated as the current is attenuated by co-expression of 
the pleckstrin homology domain of the beta adrenergic receptor kinase (βARK), a well 
characterized Gβγ scavenger (Fig. 3.1D). Since βARK has been implicated to bind PIP2 
and also GIRK channels directly, we used an additional Gβγ scavenger, myristoylated 
phosducin (Fig. 3.1E) (Hatcher-Solis, Fribourg et al. 2014). Figure 3.1F is a summary 
figure establishing the DA-elicited current (-17.23 ± 2.35 µA) as significantly different 
from the G1/2 basal current (-7.32 ± 0.43 µA). Paired t-tests were performed to compare 
“Basal” to “Basal + Agonist” currents in the five different expression groups. Significant 
effects were noted in the “G1/G2 + D2R” expression group, p=0.005. Only the Barium 
(Ba2+)-sensitive current was analyzed for figure 3.1F as Ba2+ is a blocker of GIRK 
currents. After characterizing homomeric D2R signaling, we pursued an 
electrophysiological assay to assess the effect of A2AR-D2R heteromerization on 
homomeric D2R signaling.  
After characterizing Gi signaling through the D2R, we tested the effect of 
heteromerization. A2ARs and D2Rs are known to have two types of interactions: 1) direct 
receptor-receptor interactions or heteromerization and 2) downstream signaling from 
separate populations of homomers converging on effector molecules (Ferre, Agnati et 
al. 2007). When assessing the effect of A2AR-D2R heteromerization, we blocked the 
downstream signaling of the adjacent GPCR so changes in homomeric signaling should 
result from heteromerization. Thus, while examining D2R-mediated signaling through 
the A2AR-D2R heteromer, we did not co-express Gαs to affect A2AR signaling (Lim, 
Dascal et al. 1995).  
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To test the effect of heteromerization on Gi signaling through the D2R, different 
D2R:A2AR cRNA ratios were used to achieve the level of protein expression for maximal 
signaling through heteromerization. Downstream A2AR signaling was blocked by not 
overexpressing Gαs since the endogenous level of Xenopus Gαs is not sufficient to elicit 
signaling through the A2AR (Lim, Dascal et al. 1995). Compared to Gi signaling through 
the D2R (Fig. 3.2A), there is decreased D2R signaling with A2AR co-expression 
(D2R:A2AR) in the following ratios: 1:1 (Fig. 3.2B), 1:2 (Fig. 3.2C), and 2:1 (Fig. 3.2D).  
Figure 3.2E is a summary figure of the normalized Ba2+-sensitive, DA-induced current 
showing A2AR co-expression significantly reduces Gi signaling through the D2R in all 
ratios tested. Paired t-tests with a Bonferroni correction were performed to compare 
normalized Gi activity with and without A2AR co-expression (1:0, 2.84 ± 0.14). Significant 
effects were noted in all the D2R:A2AR expression groups: 1:1 (2.26 ± 0.12), 1:2 (2.06 ± 
0.09), and 2:1 (1.95 ± 0.10), p<0.05. In summary, we have established an 
electrophysiological assay demonstrating that the unliganded A2AR is a negative 
allosteric modulator for D2R signaling. 
Next, we evaluated whether A2AR ligands could crosstalk to Gi signaling through 
the D2R. The ratio of D2R:A2AR used was 2:3 (0.5 ng to 0.75 ng) because previous 
studies established that this ratio is most similar to that seen in the striatum. D2R 
signaling (Figs. 3.3A and 3.4A) and the effect of A2AR co-expression (Figs. 3.3B and 
3.4B) were repeated to compare Gi activity within the same experiment. The A2AR 
agonist CGS 21680 partially removed the inhibition of the unliganded A2AR on the D2R, 
but did not restore D2R signaling to the level observed when the D2R is expressed alone 
(Figs. 3.3C and 3.4C). Perfusion of the A2AR antagonists KW-6002 (Fig. 3.3D) and ZM 
47 
241385 (Fig. 3.4D) resulted in Gi signaling that was not significantly different from that 
displayed with the D2R. Interestingly, the combination of CGS 21680 and the A2AR 
antagonists KW-6002 (3.3E) and ZM 241385 (Fig. 3.4E) resulted in Gi signaling through 
the D2R that was not significantly different from Gi signaling though the D2R protomer. 
Figures 3.3 and 3.4 demonstrate that the addition of A2AR ligands can further modulate 
the inhibition of the unliganded A2AR on D2R signaling. 
 After evaluating A2AR-D2R crosstalk, we sought to determine if the allosteric 
modulation of the A2AR on the D2R was due to heteromerization; therefore, we mutated 
the heteromer interface (Fig. 3.5) and tested the A2AR ligands on homomeric D2R 
signaling (Fig. 3.7). We utilized A2AR(S374A) to disrupt heteromerization and test if this 
mutant affected the ability of A2AR ligands to crosstalk to the D2R. In all ligand 
combinations tested, co-expressing A2AR(S374A) with the WT D2R abrogated the effect 
of the A2AR ligands CGS 21680 (Fig. 3.5C), ZM 241385, (Fig. 3.5D) KW-6002 (Fig. 
3.5E), CGS 21680 + ZM 241385 (Fig.3.5F), and CGS 21680 + KW-6002 (Fig. 3.5G) on 
D2R signaling. In figure 3.6, the A2AR mutant A2AR(S374A) (3.6B) was shown to have Gi 
signaling that was not significantly different from the WT A2AR (Fig. 3.6A). Thus, the 
difference in function between A2AR(S374) and A2AR was not the reason for the 
termination of the A2AR-mediated effects on D2R signaling. We also tested all of the 
A2AR ligands used in previous figures to assess if these ligands exerted independent 
effects on D2R signaling. Compared to dopamine-elicited D2R signaling, neither CGS 
21680, ZM 241385, nor KW-6002 had any effect on D2R signaling. Furthermore, these 
ligands did not have any effect on basal D2R signaling. Figures 3.5, 3.6, and 3.7 provide 
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additional evidence that the antagonism of A2AR ligands on D2R signaling was due to 
heteromerization.  
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3.3 Discussion  
 GPCR heteromers are emerging therapeutic targets for a plethora of diseases 
due to cell-specific localization and distinct pharmacology from their homomeric or 
monomeric counterparts (Ferre, Quiroz et al. 2008). The A2AR-D2R heteromer is of 
interest since the reciprocal antagonistic interaction can be exploited to develop novel 
antiparkinsonian therapeutics (Ferre, Agnati et al. 2007). Signaling through the D2R 
inhibits the neuronal excitability of striatal enkephalinergic MSNs allowing normal 
circuitry through the indirect motor pathway to the motor cortex resulting in the initiation 
of movement. Through heteromerization, the A2AR antagonizes D2R signaling 
modulating neuronal excitability and GABA release. In cases of Parkinson’s disease, 
decreased homomeric D2R signaling combined with heteromer-mediated A2AR 
antagonism on residual dopaminergic signaling increases inhibitory GABAergic 
projections from the basal ganglia to the ventrolateral thalamus disrupting thalamic 
output to the motor cortex to initiate movement (Kull, Ferre et al. 1999). Consequently, 
the A2AR antagonists istradefylline (KW-6002), vipadenant, and tozadenant have been 
explored for Parkinson’s disease pharmacotherapy in clinical trials (Jenner 2003). 
Therefore, characterization of A2AR-D2R heteromer signaling could elucidate the 
molecular mechanism for A2AR antagonists potentiating D2R signaling and being 
efficacious therapeutics for Parkinson’s disease.  
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In the current study, we have developed electrophysiological assays to 
characterize the effect of A2AR-D2R heteromerization on signaling through the D2R. 
Two-electrode voltage-clamp was used to measure current through the GIRK1/2 
channel, which served as a reporter for G protein signaling through the D2R, or A2AR-
D2R heteromer in the Xenopus laevis oocyte heterologous expression system. Our 
results demonstrate GIRK channels can serve as reporters for Gi-coupled signaling 
through the D2R (Fig. 3.1). Previous studies revealed A2AR antagonism of D2R signaling 
effects on neurotransmitter release, neural firing, and behavior (Agnati, Ferre et al. 
2003, Ferre, Agnati et al. 2007, Azdad, Gall et al. 2009). Consistent with previous 
findings, our work demonstrates that mere co-injection of the A2AR reduces D2R 
signaling (Fig. 3.2). Our study is the first to demonstrate that the unliganded A2AR 
antagonizes Gi signaling through the D2R. Furthermore, the addition of the A2AR ligand 
agonist CGS 21680 in combination with dopamine relieved the inhibition of the 
unliganded A2AR on D2R signaling even though Gi signaling was not equivalent to the 
level when the D2R is expressed alone. In contrast, the combination of A2AR antagonists 
KW-6002 and ZM 241385 with dopamine inhibited D2R signaling similarly to the 
unliganded A2AR. The combination of CGS 21680 with either KW-6002 or ZM 241385 
resulted in Gi signaling through the D2R that is similar to that displayed when the D2R is 
expressed alone (Figs. 3.3, 3.4, and 3.8). Crosstalk was mediated by heteromerization 
because abrogating the heteromer interface using A2AR(S374A) abolished the inhibition 
of A2AR ligands on D2R signaling (Figs. 3.5, 3.6, and 3.8). Our data provide evidence at 
the molecular level for the combination of agonists and antagonists for the A2AR 
potentially being effective as putative antiparkinsonian therapeutics. These results are 
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consistent with the findings of Bonaventura et al. 2015, which examined the effect of 
A2AR ligands on D2R signaling at the second messenger and behavioral level. Overall, 
we demonstrate that the A2AR antagonizes Gi-mediated D2R signaling through 
heteromerization at the G protein level and we have developed an assay for the 
screening of A2AR ligands against Gi signaling through the D2R.  
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Figure 3.1. The GIRK1/2 (G1/2) channel is a suitable reporter or Gi signaling 
through the D2R. Representative barium-sensitive traces of G1/2 currents obtained in 
response to a high K+ solution (HK, solid line) and 1 µM dopamine (DA, dashed line) in 
oocytes expressing G1 + G2 (3.1A), G1 + G2 + D2R (3.1B), G1 + G2 + D2R + PTX 
(3.1C), G1 + G2 + D2R + βARK (3.1D), and G1 + G2 + D2R + PHOS (3.1E). Barium (3 
mM Ba2+, dotted line) inhibited G1/2 and allowed for subtraction of G1/2 independent 
currents. βARK and PHOS are proteins that bind Gβγ, acting as scavengers. Summary 
figure where each bar represents the mean of n=5-6 experiments with error bars 
depicting the standard error of the mean (3.1F). Significance was determined using a 
paired t-test p<0.01.  
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Figure 3.2. A2AR coexpression in various ratios to the D2R inhibits Gi signaling 
through the D2R. Representative barium-sensitive traces of G1/2 currents obtained in 
response to a high K+ solution (HK, solid line) and 1 µM dopamine (DA, dashed line) in 
oocytes expressing G1 + G2 + D2R (1 ng, 3.2A), G1 + G2 + D2R + A2AR (0.5 ng, 3.2B), 
G1 + G2 + D2R + A2AR (1 ng, 3.2C), and G1 + G2 + D2R + A2AR (2 ng, 3.2D). Barium (3 
mM Ba2+, dotted line) inhibited G1/2 and allowed for subtraction of G1/2 independent 
currents. Summary figure where each bar represents the mean of n=5-6 experiments 
with error bars depicting the standard error of the mean (3.2E). Significance was 
determined using a one-way ANOVA with a Tukey’s posttest, p<0.05. 
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Figure 3.3. A2AR ligands crosstalk to the D2R. Representative barium-sensitive traces 
of G1/2 currents obtained in response to a high K+ solution (HK, solid line) and 1 µM 
dopamine (DA, dashed line); 1 µM dopamine + 10 µM CGS 21680 (DA + CGS, dashed 
line); 1 µM dopamine + 10 µM KW-6002 (DA + KW, dashed line); or 1 µM dopamine + 
10 µM CGS 21680 + 10 µM KW-6002 (DA + CGS + KW, dashed line). Oocytes 
expressed G1 + G2 + D2R (0.5 ng, 3.3A), or G1 + G2 + D2R + A2AR (0.75 ng, 3.3B, 
3.3C, 3.3D, 3.3E). Barium (3 mM Ba2+, dotted line) inhibited G1/2 and allowed for 
subtraction of G1/2 independent currents. Summary figure where each bar represents 
the mean of n=5-8 experiments with error bars depicting the standard error of the mean 
(3.3F). Significance was determined using a one-way ANOVA with a Tukey’s posttest, 
p<0.05. 
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Figure 3.4. A2AR ligands crosstalk to the D2R continued. Representative barium-
sensitive traces of G1/2 currents obtained in response to a high K+ solution (HK, solid 
line) and 1 µM dopamine (DA, dashed line); 1 µM dopamine + 10 µM CGS 21680 (DA + 
CGS, dashed line); 1 µM dopamine + 10 µM ZM 241385 (DA + ZM, dashed line); or 1 
µM dopamine + 10 µM CGS 21680 + 10 µM ZM 241385 (DA + CGS + ZM, dashed line). 
Oocytes expressed G1 + G2 + D2R (0.5 ng, 3.4A), or G1 + G2 + D2R + A2AR (0.75 ng, 
3.4B, 3.4C, 3.4D, 3.4E). Barium (3 mM Ba2+, dotted line) inhibited G1/2 and allowed for 
subtraction of G1/2 independent currents. Summary figure where each bar represents 
the mean of n=5-8 experiments with error bars depicting the standard error of the mean 
(3.3F). Significance was determined using a one-way ANOVA with a Tukey’s posttest, 
p<0.05. 
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Figure 3.5. A2AR(S374A) abolishes crosstalk of A2AR ligands to Gi signaling 
through the D2R. Representative barium-sensitive traces of G1/2 currents obtained in 
response to a high K+ solution (HK, solid line) and 1 µM dopamine (DA, dashed line); 1 
µM dopamine + 10 µM CGS 21680 (DA + CGS, dashed line); 1 µM dopamine + 10 µM 
ZM 241385 (DA + ZM, dashed line) 1 µM dopamine + 10 µM KW-6002 (DA + KW, 
dashed line); 1 µM dopamine + 10 µM CGS 21680 + 10 µM ZM 241385 (DA + CGS + 
ZM, dashed line); or 1 µM dopamine + 10 µM CGS 21680 + 10 µM KW-6002 (DA + 
CGS + KW, dashed line). Oocytes expressed G1 + G2 + D2R (0.5 ng, 3.5A), or G1 + 
G2 + D2R + A2AR(S374A,0.75 ng, 3.5B, 3.5C, 3.5D, 3.5E, 3.5F, 3.5G). Barium (3 mM 
Ba2+, dotted line) inhibited G1/2 and allowed for subtraction of G1/2 independent 
currents. Summary figure where each bar represents the mean of n=5-8 experiments 
with error bars depicting the standard error of the mean (3.5H). Significance was 
determined using a one-way ANOVA with a Tukey’s posttest, p<0.05. 
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Figure 3.6. A2AR(S374A) is functionally similar to WT A2AR. Representative barium-
sensitive traces of G1/2 currents obtained in response to a high K+ solution (HK, solid 
line) and 10 µM CGS 21680 (CGS, dashed line) in oocytes expressing G1 + G2 + Gαs + 
A2AR (3.6A), or G1 + G2 + Gαs + A2AR(S374A, 3.6B). Barium (3 mM Ba2+, dotted line) 
inhibited G1/2 and allowed for subtraction of G1/2 independent currents. Summary 
figure where each bar represents the mean of n=5-8 experiments with error bars 
depicting the standard error of the mean (3.6C). Significance was determined using a 
paired t-test, p<0.05. 
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Figure 3.7. A2AR ligands do not agonize or antagonize homomeric D2R Gi activity. 
Summary figure of oocytes expressing G1 + G2 + D2R where each bar represents the 
mean of n=5-8 experiments with error bars depicting the standard error of the mean. 
Oocytes were perfused with 1 µM Dopamine (DA), 10 µM CGS 21680 (CGS), 10 µM 
ZM 241385 (ZM), 10 µM KW-6002 (KW), 1 µM DA + 10 µM CGS, 1 µM DA + 10 µM 
ZM, or 1 µM DA + 10 µM KW. Significance was determined using a one-way ANOVA 
with a Tukey’s posttest.  
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Figure 3.8 Summary D2R Signaling. Perfusion of DA to an oocyte injected with cRNA for 
the D2R, GIRK1, and GIRK2 leads to channel activation resulting in robust agonist-induced 
current (left panel, 3.1B). Co-expression of the unliganded A2AR with blocked downstream 
signaling results in a decrease of the DA-elicited current through the D2R (second panel, 3.4B). 
Application of the A2AR agonist CGS-21680 results in a relief of the inhibition of the unliganded 
A2AR. Application of the A2AR antagonists KW-6002 or ZM241385 results in inhibition similar to 
that seen with the unliganded A2AR. Co-application of A2AR agonists and antagonists results in a 
relief of inhibition similar to that seen with perfusion of CGS-21680 alone (third panel). 
Disrupting the heteromer interface using A2AR(S374A) abrogates all crosstalk.  	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Chapter 4 THE EFFECT OF HETEROMERIZATION ON GS SIGNALING THROUGH 
 
THE A2AR 
 
 
 
4.1 Introduction 
 
 The Gαs/olf-coupled A2AR and the Gαi/o-coupled D2R are two distinct GPCRs that  
 
heteromerize in the striatopallidal GABA pathway (Ferre, Quiroz et al. 2008). Previous  
 
studies determined that heteromerization depends on electrostatic interactions between  
 
an arginine rich region in the third intracellular loop of the D2R and a phosphorylated  
 
serine (Ser374) in the c-terminus of the A2AR (Borroto-Escuela, Marcellino et al. 2010).  
 
The physiological relevance of the A2AR-D2R heteromer is based on receptor  
 
antagonism. A2ARs antagonize the inhibitory role of D2Rs on neurotransmitter release  
 
and neuronal firing.  There is exaggerated antagonism of the D2R by the A2AR in  
 
Parkinson’s disease patients due to decreased dopaminergic tone in the striatum (Kull, 
Ferre et al. 1999). Therefore, A2AR antagonists are being explored as possible 
therapeutics for Parkinson’s disease because they alleviate the A2AR inhibition  
of the D2R (Fuxe, Ferre et al. 2007). A plethora of studies have explored the  
 
antagonism of the A2AR on the D2R, but few studies have examined the antagonism of  
 
the D2R on A2AR signaling. Fernández-Dueñas et al. 2013 provided evidence for D2R  
 
agonists (e.g. apomorphine, rotigotine, and pramipexole) antagonizing A2AR agonist  
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binding, but this study did not examine the effect of D2R ligands on A2AR signaling  
 
(Fernandez-Duenas, Gomez-Soler et al. 2013). Therefore, we aim to further understand  
 
A2AR signaling through the A2AR-D2R complex. We will study A2AR-D2R heteromer cross  
 
signaling through the GS-coupled A2AR by expressing the GPCRs as well as reporter  
 
channels using the Xenopus oocyte heterologous expression system. Our  
 
electrophysiological assay is innovative in that it will allow us to control the conditions of  
 
heteromerization to tease apart the differences from protomer signaling. Based on  
 
previous studies, we hypothesize that D2R agonists will inhibit Gs signaling through the  
 
A2AR and specific ligand combinations targeting the A2AR-D2R heteromer will be more  
 
effective in maximizing GPCR signaling than individual drug administration.  
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4.2 Results 
 
Lim et al. 1995 demonstrated in Xenopus oocytes that GIRK channels could 
couple to the β2 adrenergic receptor when Gαs is over expressed with the channel. 
Using a similar approach, we determined G1/2 as a suitable reporter for Gs signaling 
through the A2AR when Gαs is over expressed (Lim, Dascal et al. 1995). Figures 4.1A-C 
serve as negative controls establishing that the G1/2 channel can only couple to Gas 
with current elicited by the A2AR agonist CGS-21680 (CGS) when the channel is co-
expressed with both the A2AR and Gas. Figure 4.1D shows 10 µM CGS induces an 
inward current mediated by Gs signaling through the A2AR when Gas, G1/2, and A2AR 
are co-expressed validating G1/2 as a reporter for Gs signaling. Figure 4.1E 
demonstrates the CGS-elicited current is Gβγ-mediated, as it is abolished by the Gβγ 
scavenger βARK. Myristoylated phosducin was also used as a specific Gβγ scavenger 
(Fig. 4.1F). Figure 4.1G is a summary figure of the Ba2+-sensitive current showing the 
CGS-induced current (-11.58 ± 0.98 µA) is significantly different from G1/2 basal current 
(-4.80 ± 0.30 µA). Paired t-tests were performed to compare “Basal” to “Basal + 
Agonist” in the six different expression groups. Significant effects were noted in the “G1 
+ G2 + Gαs + A2AR” expression group, p=0.02. Signaling through the A2AR was also 
examined with PTX co-injection. Compared to CGS-elicited signaling through the A2AR 
(Fig. 4.1D), addition of PTX reduced the basal G1/2 current and the CGS-induced 
current (Figs. 4.2B,C). Paired t-tests were performed to compare “Basal” (-7.05 ± 0.66 
µA) to “Basal (+ PTX)” current (-4.16 ± 0.61 µA) and “Agonist” (-3.78 ± 0.43 µA) to 
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“Agonist (+ PTX)” (-2.82 ± 0.41 µA) current in the two different treatment groups, 
p<0.05. A2AR-mediated Gαs signaling persisted in the presence of PTX confirming Gs 
signaling is independent of Gi signaling in our assay. In summary, we have established 
electrophysiological assays using G1/2 for signaling through the A2AR.  
Adenosine (ADO), the nonselective endogenous ligand for the A2AR, was not 
used in our assay for A2AR signaling because Xenopus oocytes have an endogenous 
Gi-coupled adenosine type 1 receptor (A1R, Fig. 4.3D). In oocytes only injected with 
G1/2 cRNA, ADO elicited a robust agonist-induced current (Fig. 4.3A). Furthermore, N6-
cyclopentyladenosine (CPA), a selective A1R agonist, stimulated agonist-induced 
current (Fig. 4.3C) while CGS, a selective A2AR agonist, did not (Fig. 4.3B). Figure 4.3D 
is a summary figure of the Ba2+-sensitive current showing the ADO-induced current (-
7.79 ± 0.58 µA) and the CPA-induced current (-11.36 ± µA) are significantly different 
from the G1/2 basal current for the “ADO” (-3.19 ± 0.14 µA) and “CPA” (-5.46 ± 0.50 µA) 
treatment groups. Paired t-tests were performed to compare “Basal” to “Basal + 
Agonist” in the three different treatment groups. Significant effects were noted in the 
“ADO” and “CPA” expression groups, p<0.01. 
After characterizing protomeric signaling through the A2AR, we tested the effect 
of heteromerization. A2ARs and D2Rs are known to have two types of interactions: 1) 
direct receptor-receptor interactions or heteromerization and 2) downstream signaling 
from separate populations of homomers converging on effector molecules (Ferre et al. 
2007) When assessing the effect of A2AR-D2R heteromerization, we blocked the 
downstream signaling of the adjacent GPCR so changes in signaling should result from 
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heteromerization. A2AR-mediated signaling through the A2AR-D2R heteromer was 
evaluated with PTX co-expression to abrogate D2R signaling.  
Our lab is the first to examine the functional implications of A2AR-D2R 
heteromerization on A2AR signaling using electrophysiology (Fig. 4.4). We tested the 
effect of heteromerization on Gs signaling through the A2AR using different A2AR:D2R 
cRNA ratios to achieve the level of protein expression for maximal cross-signaling. PTX 
was co-expressed to block downstream D2R signaling. Compared to Gs signaling 
through the A2AR (Fig. 4.4A), there is decreased A2AR signaling with D2R co-expression 
(A2AR:D2R) in the following ratios: 1:1 (Fig. 4.4B), 1:2 (Fig. 4.4C), and 2:1 (Fig. 4.4D).  
Figure 4.4E is a summary figure of the normalized Ba2+ -sensitive, CGS-induced current 
showing D2R co-expression significantly reduces Gs signaling through the A2AR in all 
ratios tested. A one-way ANOVA with a Tukey’s posttest was performed to compare 
normalized Gs activity with and without D2R co-expression (1:0, 2.12 ± 0.23). Significant 
effects were noted in all the A2AR:D2R expression groups: 1:1 (1.64 ± 0.08), 1:2 (1.45 ± 
0.08), and 2:1 (1.39 ± 0.05), p<0.05. Thus, we have established an electrophysiological 
assay demonstrating that the D2R antagonizes A2AR signaling.  
Next, we evaluated whether D2R ligands could crosstalk to Gs signaling through 
the A2AR. The ratio of D2R:A2AR used was 2:3 (0.5 ng to 0.75 ng) because previous 
studies have established that this ratio is most similar to that seen in the striatum. A2AR 
signaling (Fig. 4.5A) and the effect of D2R co-expression (Fig. 4.5B) were repeated to 
compare Gs activity within the same experiment. Perfusion of the D2R agonist quinpirole 
(Fig. 4.5C) or the D2R antagonists paliperidone (Fig. 4.5D) and amisulpride (Fig. 4.5E) 
resulted in Gs signaling that was significantly decreased from that displayed with co-
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expression of the unliganded D2R. The combination of the D2R ligands quinpirole and 
paliperidone inhibited Gs signaling through the A2AR at similar levels to that seen with 
either ligand alone (4.5F). In contrast, the combination of the D2R ligands quinpirole and 
amisulpride (4.5G) resulted in Gs signaling through the A2AR that was not significantly 
different from protomeric levels. Figure 4.5 demonstrates that the addition of D2R 
ligands can further modulate the inhibition of the unliganded D2R on A2AR signaling. 
 After evaluating A2AR-D2R crosstalk, we sought to determine if the allosteric 
modulation of the D2R on the A2AR was due to heteromerization; therefore, we mutated 
the heteromer interface (Fig. 4.6) and tested the D2R ligands on protomeric A2AR 
signaling (Fig. 4.8). We mutated arginines 217, 219, 220, 222, 267, 268, and 269 along 
with lysines 218 and 221 in the third intracellular loop of the D2R to alanine to disrupt 
heteromerization and termed the mutant D2R(9A). We utilized D2R(9A) to disrupt 
heteromerization and test if this mutant affected the ability of D2R ligands to crosstalk to 
the A2AR. In all ligand combinations tested, co-expressing D2R(9A) with the WT A2AR 
abrogated the effect of the D2R ligands quinpirole (Fig. 4.6C), paliperidone (Fig. 4.6D), 
amisulpride (Fig. 4.6E), quinpirole + paliperidone (Fig. 4.6F), and quinpirole + 
amisulpride (Fig. 4.6G) on A2AR signaling. In figure 4.7, the D2R mutant D2R(9A, Fig. 
4.7B) was shown to have Gi signaling that was not significantly different from the WT 
A2AR (Fig. 3.6A). Thus, the difference in function between D2R(9A) and D2R was not the 
reason for the termination of the D2R-mediated effects on A2AR signaling. We also 
tested all of the D2R ligands used in previous figures to assess if these ligands exerted 
independent effects on A2AR signaling. Compared to CGS 21680-elicited A2AR 
signaling, neither quinpirole, paliperidone, nor amisulpride had any effect on protomeric 
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A2AR signaling. Furthermore, these ligands did not have any effect on basal A2AR 
signaling. Figures 4.6, 4.7, and 4.8 provide additional evidence that the antagonism of 
A2AR ligands on D2R signaling was due to heteromerization.  
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4.3 Discussion 
 
The A2AR-D2R heteromer is an emerging therapeutic target for Parkinson’s 
disease because of the established antagonism of the A2AR on the D2R. In Parkinson’s 
disease, there is a loss of dopaminergic innervation to the striatum and the A2ARs 
antagonize residual D2R signaling. Therefore, most studies have focused on elucidating 
the antagonism of the A2AR on the D2R targetting A2AR antagonists as antiparkinsonian 
therapeutics (Jenner 2003). The A2AR antagonist KW-6002 is currently used in Japan to 
treat Parkinson’s disease and several other A2AR antagonists are in clinical trials (Chen, 
Wang et al. 2013). Compared to the extensive research characterizing A2AR 
antagonism of the D2R, much less is known of the D2R-mediated antagonism of the 
A2AR. Various studies have detailed the antagonism of the D2R on the A2AR at the 
second messenger level through the canonical Gi signaling pathway inhibiting adenylate 
cyclase, cAMP accumulation, PKA phosphorylation of downstream effectors, and gene 
expression of c-fos and preproenkephalin (Ferre, Quiroz et al. 2008). However, this 
negative allosterism at the second messenger level is not heteromer dependent. Fewer 
studies have focused on the therapeutic potential of D2R agonists that crosstalk to the 
A2AR through heteromerization inhibiting A2AR ligand binding and signaling. In 2013, 
Fernández-Dueñas and colleagues used real-time FRET and flow cytometry in 
transfected cells to provide evidence for antiparkinsonian D2R agonists antagonizing 
A2AR agonist binding. More studies are needed to examine the effect of D2R ligands on 
A2AR signaling through heteromerization as this could lead to novel antiparkinsonian 
therapeutics targeting the D2R.  
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Expanding on the Fernández-Dueñas study, we developed an 
electrophysiological assay to examine the effect of A2AR-D2R heteromerization on A2AR 
signaling at the G protein level. We used Xenopus laevis occytes as our heterologous 
expression system and the GIRK1/2 channel as a reporter for A2AR signaling by over 
expressing Gαs (Fig. 4.1). In our assay, co-expression of the unliganded D2R inhibits 
A2AR signaling (Fig. 4.4). Our study is one of the first to demonstrate that the unliganded 
D2R antagonizes Gs signaling through the A2AR. Furthermore, the addition of the D2R 
agonist quinpirole or the D2R antagonists paliperidone and amisulpride further inhibited 
signaling through the A2AR (Fig. 4.5 and Fig. 4.9). Our work provides evidence for both 
D2R agonists and antagonists diminishing Gs signaling through the A2AR. The 
combination of the D2R ligands quinpriole and paliperidone inhibited A2AR signaling 
similarly to each ligand when administered alone. In contrast, co-administration of 
quinpirole and amisulpride resulted in Gs signaling through the A2AR that is similar to 
protomeric levels (Fig. 4.5). Crosstalk was mediated by heteromerization because 
abrogating the heteromer interface using D2R(9A) abolished the inhibition of D2R 
ligands on A2AR signaling (Figs. 4.6, 4.7, and 4.9). Overall, we have demonstrated that 
the D2R antagonizes Gs-mediated A2AR signaling through heteromerization at the G 
protein level and we have developed an assay for the screening of D2R ligands against 
Gs signaling through the A2AR.  
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Figure 4.1 The GIRK1/2 (G1/2) channel is a suitable reporter for Gs signaling 
through the A2AR. Representative barium-sensitive traces of G1/2 currents obtained in 
response to a high K+ solution (HK, solid line) and 10 µM CGS-21680 (CGS, dashed 
line) in oocytes expressing G1 + G2 (4.1A), G1 + G2 + Gαs (4.1B), G1 + G2 + A2AR 
(4.1C), G1 + G2 + Gαs + A2AR (4.1D), G1 + G2 + Gαs + A2AR + βARK (4.1E), and G1 + 
G2 + Gαs + A2AR + PHOS (4.1F). Barium (3 mM Ba2+, dotted line) inhibited G1/2 and 
allowed for subtraction of G1/2 independent currents. Summary figure where each bar 
represents the mean of n=5-6 experiments with error bars depicting the standard error 
of the mean (4.1G). Significance was determined using a paired t-test p<0.03. 
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Figure 4.2 Gs signaling through the A2AR in the presence of PTX. Representative 
barium-sensitive traces of G1/2 currents obtained in response to a high K+ solution (HK, 
solid line) and 10 µM CGS-21680 (CGS, dashed line) in oocytes expressing G1 + G2 + 
Gαs + A2AR (4.2A) and G1 + G2 + Gαs + A2AR + PTX (4.2B). Barium (3 mM Ba2+, 
dotted line) inhibited G1/2 and allowed for subtraction of G1/2 independent currents. 
Summary figure where each bar represents the mean of n=5-6 experiments with error 
bars depicting the standard error of the mean (4.2C). Significance was determined with 
a paired t-test, p<0.05. 
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Figure 4.3 Xenopus oocytes have an endogenous Gi-coupled A1R. Representative 
barium-sensitive traces of G1/2 currents obtained in response to a high K+ solution (HK, 
solid line) and 10 µM adenosine (ADO, dashed line) the nonselective endogenous 
ligand for adenosine receptors (4.3A), 10µM CGS-21680 (CGS, dashed line) the 
selective agonist for the A2AR (4.3B), and 10 µM N6-cyclopentyladenosine (CPA, 
dashed line) the selective agonist for the A1R (4.3C). Barium (3 mM Ba2+, dotted line) 
inhibited G1/2 and allowed for subtraction of G1/2 independent currents. Summary 
figure where each bar represents the mean of n=5-6 experiments with error bars 
depicting the standard error of the mean (4.3D). Significance was determined using a 
paired t-test p<0.01. 
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Figure 4.4 The effect of D2R co-expression on Gs signaling through the A2AR. 
Representative barium-sensitive traces of G1/2 currents obtained in response to a high 
K+ solution (HK, solid line) and 10 µM CGS-21680 (CGS, dashed line) in oocytes 
expressing G1, G2, the A2AR, PTX and D2R in the following ratios: 1:0 (4.4A), 1:1 
(4.4B), 1:2 (4.4C), and 2:1 (4.4D). Barium (3 mM Ba2+, dotted line) inhibited G1/2 and 
allowed for subtraction of G1/2 independent currents. Summary figure of normalized Gs 
activity (Agonist + Basal Current/ Basal Current) where each bar represents the mean of 
n=4-6 experiments with error bars depicting the standard error of the mean (4.4E). 
Significance was determined using a one-way ANOVA with a Tukey’s posthoc test, 
p<0.05. 
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Figure 4.5 D2R ligands crosstalk to the A2AR. Representative barium-sensitive traces 
of G1/2 currents obtained in response to a high K+ solution (HK, solid line) and 10 µM 
CGS 21680 (CGS, dashed line); 10 µM CGS 21680 + 1 µM quinpirole (CGS + QUIN, 
dashed line); 10 µM CGS 21680 + 10 µM paliperidone (CGS + PAL, dashed line); or 10 
µM CGS 21680 + 10 µM amisulpride (CGS + ASUL, dashed line); 10 µM CGS 21680 + 
1 µM quinpirole + 10 µM paliperidone (CGS + QUIN + PAL, dashed line); or 10 µM CGS 
21680 + 1 µM quinpirole + 10 µM amisulpride. Oocytes expressed G1 + G2 + Gαs + 
PTX+ A2AR (0.75 ng, 4.5A), or G1 + G2 + D2R + PTX+ Gαs + A2AR (0.75 ng, 4.5B, 
4.5C, 4.5D, 4.5E, 4.5F, 4.5G). Barium (3 mM Ba2+, dotted line) inhibited G1/2 and 
allowed for subtraction of G1/2 independent currents. Summary figure where each bar 
represents the mean of n=5-8 experiments with error bars depicting the standard error 
of the mean (4.5H). Significance was determined using a one-way ANOVA with a 
Tukey’s posthoc test, p<0.05. 
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Figure 4.6 D2R-9A disrupts the allosteric modulation of the D2R on the A2AR. We 
mutated arginines 217, 219, 220, 222, 267, 268, and 269 along with lysines 218 and 
221 in the third intracellular loop of the D2R to alanine to disrupt heteromerization and 
termed the mutant D2R D2R(9A). Representative barium-sensitive traces of G1/2 
currents obtained in response to a high K+ solution (HK, solid line) and 10 µM CGS 
21680 (CGS, dashed line); 10 µM CGS 21680 + 1 µM quinpirole (CGS + QUIN, dashed 
line); 10 µM CGS 21680 + 10 µM paliperidone (CGS + PAL, dashed line) 10 µM CGS 
21680 + 10 µM amisulpride (CGS + ASUL, dashed line); 10 µM CGS 21680 + 1 µM 
quinpirole + 10 µM paliperidone (CGS + QUIN + PAL, dashed line); or 10 µM CGS 
21680 + 1 µM quinpirole + 10 µM amisulpride (CGS + QUIN + ASUL, dashed line). 
Oocytes expressed G1 + G2 + Gαs + PTX + A2AR (0.75 ng, 4.6A), or G1 + G2 + 
D2R(9A)+ PTX + Gαs + A2AR(0.75 ng, 4.6B, 4.6C, 4.6D, 4.6E, 4.6F, 4.6G). Barium (3 
mM Ba2+, dotted line) inhibited G1/2 and allowed for subtraction of G1/2 independent 
currents. Summary figure where each bar represents the mean of n=5-8 experiments 
with error bars depicting the standard error of the mean (4.6H). Significance was 
determined using a one-way ANOVA with a Tukey’s posttest, p<0.05. 
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Figure 4.7 D2R-9A is functionally similar to WT D2R. Representative barium-sensitive 
traces of G1/2 currents obtained in response to a high K+ solution (HK, solid line) and 1 
µM dopamine (DA, dashed line) in oocytes expressing G1 + G2 + D2R (A), or G1 + G2 
+ D2R(9A) (B). Barium (3 mM Ba2+, dotted line) inhibited G1/2 and allowed for 
subtraction of G1/2 independent currents. Summary figure where each bar represents 
the mean of n=5-8 experiments with error bars depicting the standard error of the mean 
(C). Significance was determined using a paired t-test, p<0.05. 
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Figure 4.8 D2R ligands do not agonize or antagonize homomeric A2AR Gs activity. 
Summary figure of oocytes expressing G1 + G2 + Gαs + A2AR where each bar 
represents the mean of n=5-8 experiments with error bars depicting the standard error 
of the mean. Oocytes were perfused with 10 µM CGS 21680 (CGS), 1 µM Quinpirole 
(QUIN), 10 µM Paliperidone (PAL), 10 µM Amisulpride (ASUL), 10 µM CGS + 1 µM 
QUIN, 10 µM CGS + 10 µM PAL, or 10 µM CGS + 10 µM ASUL. Significance was 
determined using a one-way ANOVA with a Tukey’s posthoc test.  
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Figure 4.9 Summary A2AR Signaling. Perfusion of CGS to an oocyte injected with cRNA 
for the A2AR, PTX, Gαs, GIRK1, and GIRK2 leads to channel activation resulting in robust 
agonist-induced current (left panel). Co-expression of the unliganded D2R with blocked 
downstream signaling results in a decrease of the CGS-elicited current through the A2AR 
(second panel). Application of the D2R agonist Quinpirole results in increased inhibition 
compared to the unliganded D2R. Application of the D2R antagonists KW-Paliperidone or 
Amisulpride also results in increased inhibition compared to that seen with the unliganded D2R. 
Co-application of the D2R agonist Quinpirole and antagonist amisulpride results in a relief of 
inhibition (third panel). Disrupting the heteromer interface using D2R(9A) abrogates all crosstalk.  
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Chapter 5 OPTOGENETIC-MICRODIALYSIS ASSAY TO ASSESS THE 
PRESYNAPTIC PROFILE OF A2AR ANTAGONISTS 
 
 
 
 
5.1 Introduction  
 
 Smooth motor function is achieved through counterbalancing the activating and 
inhibiting influences of the direct and indirect pathways of the striatum. Dopaminergic 
innervation of the striatum results in motor activation by stimulating the direct pathway 
via D1Rs and inhibiting the indirect pathway via D2Rs. Adenosine is also an important 
neuromodulator in the striatum as stimulation or inhibition of postsynaptic A2ARs results 
in the blockade or potentiation of D2R signaling (Quiroz, Lujan et al. 2009). Striatal 
presynaptic A2ARs in glutamatergic terminals also affect motor activity by influencing 
glutamate release in the direct pathway. A2AR antagonists that inhibit postsynaptic 
A2ARs would be beneficial for the treatment of PD by inhibiting the indirect motor 
pathway and increasing motor activity. However, A2AR antagonists that inhibit 
presynaptic A2ARs would decrease glutamate release in the direct motor pathway 
inhibiting motor activity. Thus, antiparkinsonian therapeutics targeting the A2AR should 
have a higher affinity for postsynaptic versus presynaptic A2ARs. In 2011, Orrú and 
colleagues used in vitro radioligand-binding and in vivo locomotor activity experiments 
to determine the preferential presynaptic or postsynaptic action of A2AR antagonists. 
Among the A2AR antagonists tested, SCH 442416 acted predominantly on presynaptic 
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A2ARs; whereas, istradefylline (KW-6002) acted primarily on postsynaptic A2ARs. In this 
study, we have utilized the optogenetic-microdialysis technique of Quiroz-Molina et al. 
2016 to determine the presynaptic or postsynaptic preference of A2AR antagonists. We 
used optogenetics to directly stimulate the striatal MSNs of the direct pathway to induce 
glutamate release and microdialysis to determine if A2AR antagonists affect extracellular 
glutamate concentrations.  We anticipate A2AR antagonists that are potent inhibitors of 
glutamate release act primarily presynaptically. 
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5.2 Results 
 
We used an optogenetic-microdialysis probe (Fig. 5.1) implanted in the striatum  
 
of mice expressing AAV ChR2-EYFP to measure extracellular glutamate release in  
 
response to light-induced activation of the cation ChR2 (Fig. 5.2). Optogenetic  
 
stimulation resulted in rapid increases in the extracellular glutamate concentration  
 
above basal levels (~300%). Termination of the optogenetic stimulation resulted in slow  
 
decay of the extracellular glutamate concentration to basal levels. Administration of the  
 
A2AR antagonist SCH 442416 via i.p. injection before optogenetic stimulation prevented  
 
increases in the extracellular glutamate concentration (Fig. 5.4). SCH 442416 inhibited  
 
glutamate release indicating that this drug acts preferentially on presynaptic A2ARs.  
 
However, i.p. injection of the A2AR antagonist KW-6002 preceding optogenetic  
 
stimulation had no significant effect on extracellular glutamate concentration  
 
demonstrating that KW-6002 acts preferentially on postsynaptic A2ARs (Fig. 5.4). Figure  
 
5.5 is a control experiment showing that the basal levels of glutamate in the mice across  
 
all treatment groups (vehicle, SCH 442416 0.1 mg/kg, and KW-6002 1 mg/kg) obtained  
 
prior to optogenetic stimulation are not significantly different as determined by a one- 
 
way ANOVA followed by a Tukey’s posthoc test (Prism). Thus, differences in basal  
 
glutamate concentrations cannot account for the differences observed after optogenetic  
 
stimulation. Erk 1/2 phosphorylation was also examined as an indicator of neuronal  
 
activation. Robust ERK 1/2 labeling was present in the striatum of mice subjected to  
 
laser stimulation while sparse labeling was observed in the motor cortex, the site of  
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virus injection (Fig. 5.3). These experiments provide further evidence that optogenetic  
 
stimulation in the striatum, the site of probe implantation, resulted in neuronal activation  
 
and glutamate release. 
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5.3 Discussion  
 
 The A2AR-D2R heteromer is an emerginig therapeutic target for Parkinson’s 
disease based on receptor antagonism. A2AR antagonists that act postsynaptically 
through the indirect motor pathway produce motor activation by potentiating D2R 
signaling through A2AR-D2R interactions. However, A2AR antagonists that act 
presynaptically through the direct motor pathway decrease motor activity by inhibiting 
glutamate release. Therefore, it is essential to identify the presynaptic or postsynaptic 
preference of A2AR antagonists to determine their therapeutic potential as 
antiparkinsonian drugs. In this study, we have utilized an in vivo optogenetic-
microdialysis assay with the advantage of direct stimulation of glutamatergic terminals. 
Optogenetic stimulation resulted in increases the extracellular concentration of 
glutamate that were abrogated by pre-administration SCH 442416 (Fig. 5.4) Our results 
are consistent with the findings of Orrú and colleagues, who determined the potent 
activity of SCH 442416 on presynaptic A2ARs using in vitro radioligand binding and in 
vivo locomotor experiments. Future studies will involve assaying more A2AR antagonists 
especially the postsynaptic acting KW-6002 to see if this compound is able to inhibit 
glutamate release in our assay. Our assay is useful for screening the presynaptic 
activity of A2AR antagonists that are potential antiparkinsonian therapeutics.  
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Figure 5.1 Optogenetic-microdialysis probe. Image of the hand made microdialysis-
optogenetics probes with the semi-permeable microdialysis membrane, the 
microdialysis inlet and outlet, and the fiber optic (left). Illuminated microdialysis tube with 
laser stimulation (right). 
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Figure 5.2 Schematic displaying timeline of unilateral AAV microinjection and 
optogenetic-microdialysis experiment. WT C57BL/6 mice received unilateral 
injections of adeno-associated virus (AAV) encoding channel rhodopsin 2 (ChR2) fused 
to enhanced yellow fluorescent protein (EYFP) under control of the CaMKII neuronal 
promoter. The coordinates of virus injection were 1.9 mm anterior, 1.6 mm lateral, and 
1.8 mm ventral with respect to bregma to inject the virus into the motor cortex. 
Approximately, 4 weeks after virus injection a modified microdialysis probe with an 
embedded light-guiding optic fiber was implanted in the striatum. The coordinates for 
probe implantation were 0.3 mm posterior, 2.7 mm lateral and 4.2 mm ventral with 
respect to bregma in the striatum. Adapted from (Guo, Xiong et al. 2015).  
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Figure 5.3 Confocal laser microscopy of coronal sections showing the 
localization of ChR2-EYFP after unlilateral AAV microinjection in the motor cortex 
and ERK phosphorylation immunohistochemistry. A Motor Cortex, scale bar 50 uM 
B Inset C Localization of probe in striatum, scale bar 50 uM D Inset  
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Figure 5.4 Effect of optogenetic stimulation in the striatum. Time course of 
extracellular concentrations of glutamate in the striatum with i.p. injection of Vehicle, the 
A2AR antagonist SCH 442416 0.1 mg/kg, or the A2AR antagonist KW-6002 1 mg/kg. 
Negative time values represent basal glutamate before stimulation. Optogenetic 
stimulation was for 20 minutes and is represented by the blue bar. Results are 
expressed as mean ± SEM of percentages of glutamate normalized to basal values 
before stimulation, n=3-6. Results were analyzed using a two-way repeated-measures 
ANOVA with a Tukey’s posthoc test (Prism), * p≤0.05, ** p≤0.01, **** p≤0.0001.  
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Figure 5.5 Basal Glutamate Concentration. Bar graph summarizing the basal levels 
of glutamate obtained prior to optogenetic stimulation. Results are expressed as mean ± 
SEM of glutamate concentration, n=3-6. There was no significant difference between 
basal values in the three treatment groups (vehicle, SCH 442416 0.1 mg/kg, and KW-
6002 1 mg/kg) as determined by a one-way ANOVA followed by a Tukey’s posthoc test 
(Prism).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
88 
 
 
 
 
 
Chapter 6 CONCLUDING REMARKS 
 
 
 
       We investigated A2AR and D2R interactions using an electrophysiological, in vitro 
assay with Xenopus oocytes as the heterologous expression system and an in vivo, 
optogenetic-microdialysis assay in freely moving mice. Examining A2AR-D2R 
heteromerization in a heterologous expression system allowed us to manipulate the 
conditions of heteromerization by using interfering mutants. Our electrophysiological 
assay also provided a membrane-delimited, direct readout of GPCR signaling at the G 
protein level versus downstream second messengers. The Xenopus laevis heterologous 
expression system also permitted titration of A2AR and D2R expression. Similarly, there 
were many advantages to incorporating an in vivo assay into our studies. Using an in 
vivo assay allowed us to use native neurons in the mouse striatum to explore A2AR and 
D2R interactions. Through optogenetics, we were able to directly stimulate striatal 
neurons and observe glutamate release. The optogenetic-microdialysis experiments 
also provided physiological relevance to studies evaluating antiparkinsonian 
therapeutics.  Both our in vivo and in vitro assays provided a multitude of technical 
advantages that allowed key insights into A2AR-D2R interactions.  
       In chapter 3, we utilized an electrophysiological assay with GIRK channels as 
reporters for Gi signaling through the D2R to determine the effect of A2AR-D2R 
heteromerization on Gi signaling through the D2R. The following conclusions can be 
drawn from chapter 3 of this investigation. We determined that GIRK1/2 could serve as 
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a reporter for Gi signaling through the D2R as the liberated βγ subunits from D2R 
activation resulted in channel potentiation. Next, we co-expressed the A2AR along with 
the D2R and found that the unliganded A2AR antagonizes dopamine-elicited Gi signaling 
through the D2R in various ratios of overexpression of the two receptors. Our lab was 
the first to uncover the effect of the unliganded A2AR on Gi signaling through the D2R. 
We further perfused ligands to the A2AR to examine crosstalk. Perfusion of the A2AR 
agonist CGS 21680 partially relieves the inhibition of the unliganded A2AR on D2R 
signaling. Whereas, perfusing the A2AR antagonists ZM 241385 and KW-6002 both 
inhibited dopamine-elicited signaling through the D2R. The combinations of A2AR 
agonists (CGS 21680) and antagonists (KW-6002, ZM 241385) restored dopamine-
elicited Gi signaling through the D2R. We also utilized mutagenesis to examine whether 
the aforementioned crosstalk was due to heteromerization. We discovered that the 
ability of A2AR ligands to crosstalk to the D2R is mediated by A2AR-D2R heteromerization 
as disrupting the heteromer interface using A2AR(S374A) relieves the inhibition of the 
A2AR on the D2R. As a control, we tested all of the A2AR ligands used to ensure they 
were specific for the A2AR and did not have any activity on the D2R.   
 Chapter 4 of this investigation focused on using an electrophysiological assay  
 
with GIRK channels as reporters for Gs signaling through the A2AR to determine the  
 
effect of A2AR-D2R heteromerization on Gs signaling through the A2AR. We  
 
demonstrated that GIRK 1/2 can also serve as a reporter for Gs signaling through the  
 
A2AR when Gαs is overexpressed and channel activation is mediated by the liberated βγ  
 
subunits from A2AR activation. Additionally, the unliganded D2R antagonizes CGS  
 
21680-elicited Gs signaling through the A2AR in various ratios of overexpression of the  
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two receptors. Our results were the first to determine the effect of the unliganded D2R  
 
on Gs signaling through the A2AR. Next, we examined crosstalk and found that  
 
perfusion of the D2R agonist quinpirole further inhibits Gs signaling through the A2AR  
 
compared to the unliganded D2R. Furthermore, both of the D2R antagonists amisulpride  
 
and paliperidone inhibit Gs signaling through the A2AR similarly to quinpirole. The  
 
combination of the quinpirole and amilsulpride, but not quinpirole and paliperidone  
 
restored CGS 21680-elicited signaling through the A2AR to homomeric levels. We also  
 
determined that the ability of D2R ligands to crosstalk to the A2AR was mediated by  
 
heteromerization as disrupting the heteromer interface using D2R(9A, R217A, R219A,  
 
R220A, R222A, R267A, R268A, R269A, K218A and K221A) relieves the inhibition of  
 
the D2R on the A2AR. We also determined that quinpirole, amisulpride, and paliperidone  
 
were specific for the D2R and did not any extraneous effect on the homomeric A2AR.  
 
Our in vitro assays elucidated signaling through the A2AR-D2R heteromer and could  
 
provide insight for future studies examining A2AR-D2R heteromerization. 
    
In chapter 5, we utilized a recently developed optogenetic-microdialysis 
technique to examine the presynaptic profile of A2AR antagonists on glutamatergic 
afferents to the striatum. We used optogenetics to directly stimulate the striatal MSNs of 
the direct pathway to induce glutamate release and microdialysis to determine if A2AR 
antagonists affect extracellular glutamate concentrations. An optogenetic-microdialysis 
probe was implanted in the striatum of mice expressing AAV ChR2-EYFP to measure 
extracellular glutamate release in response to light-induced activation of the cation 
ChR2. Optogenetic stimulation resulted in rapid increases in the extracellular glutamate 
concentration above basal levels (~300%). Termination of the optogenetic stimulation 
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resulted in slow decay of the extracellular glutamate concentration to basal levels. 
Administration of the A2AR antagonist SCH 442416 before optogenetic stimulation 
prevented increases in the extracellular glutamate concentration. However, 
administration of the A2AR antagonist KW-6002 before optogenetic stimulation did not 
have an effect on presynaptic glutamate release. SCH 442416 inhibited glutamate 
release indicating that this drug preferentially acts on presynaptic A2ARs whereas the 
inability of KW-6002 to affect presynaptic glutamate release indicates that this drug 
preferentially acts on postsynaptic A2ARs. Erk 1/2 phosphorylation was also examined 
as an indicator of neuronal activation. Robust ERK 1/2 labeling was present in the 
striatum of mice subjected to laser stimulation while sparse labeling was observed in the 
motor cortex, the site of virus injection. Our optogenetic-microdialysis assay is  
useful for evaluating the therapeutic potential of antiparkinsonian drugs. Futures studies  
 
for the in vitro experiments will include dose-response curves to evaluate how different  
 
concentrations of A2AR and D2R ligands affect A2AR-D2R heteromer crosstalk. We are  
 
also currently developing an optogenetic-locomotor activity assay to examine the  
 
postsynaptic profile of A2AR antagonists.  
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